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Abstract 
STAT proteins were discovered as the mediators of interferon (IFN) signalling in response to viral 
infections. Later, it has become evident that STATs are activated by many stimuli and that they 
exert multifaceted effects by regulating gene transcription. Of seven members of the STAT family, 
my thesis dealt with STAT1, STAT2, and STAT3 and the genes regulated by transcriptional 
complexes containing them. STAT1 and STAT3 were believed to regulate the opposing functions, 
the former acting as a tumour suppressor and the latter being an oncogene.  
Type I IFNs have been used for the treatment of infectious diseases and some types of cancer. In 
Paper I, we investigated pathways involved in the IFN-induced apoptosis in a myeloma cell line, 
and what role the STAT1 phosphorylation plays in this model. We used chemical inhibitors of 
pSTAT1, Akt, mTOR, and cells with a dominant-negative mutant form of STAT1 to evaluate which 
pathways are essential for the pro-apoptotic effect of IFNα. We have found that pSTAT1 is 
important, but cooperation with other signalling pathways is necessary to maximize the pro-
apoptotic effect of IFNα. 
In paper II, we used multicellular spheroids (3D culture) as a model to study a gene signature 
associated with drug resistance. We have found that STAT1, STAT2, and IRF9, as well as IFN-
stimulated genes (ISGs), have increased expression in this drug resistance model. Moreover, a 
similar gene signature is induced in cells cultured for a prolonged time with no trace of IFN 
detected. The expression of ISGs was not STAT1 dependent but was controlled by STAT2 and 
IRF9. Overexpression of IRF9 alone was sufficient to drive the transcription of the ISGs and to 
induce drug resistance in the cells. Therefore, IRF9-induced gene signature can be explored as a 
marker for therapy response in cancer. 
In Paper III, we studied the role of the constitutively activated STAT3 in the sensitivity of multiple 
myeloma cells to the Hsp90 inhibitors treatment. We used a panel of cell lines categorised by 
different basal levels of the pTyr705STAT3 and of CD45 and found that the sensitivity of myeloma 
cells to an Hsp90 inhibitor correlated with the presence of pSTAT3. Using samples from multiple 
myeloma patients, we have demonstrated that it is the pSTAT3+CD45+ cell population that 
undergoes apoptosis in response to the Hsp90 inhibitor treatment. Thus, pSTAT3/CD45 can be used 
as a stratification marker for the use of these drugs. 
In Paper IV, we attempted to develop new inhibitors targeting STAT3. After the screening 
campaign, we have chosen several inhibitors that preferentially affect the viability in STAT3-
dependent cell lines. The inhibitors have different effects on the phosphorylation of STAT3 and 
STAT1, but regardless of that, all the compounds interfere with the STAT3-driven gene 
transcription. One of the compounds, KI16, preferentially inhibits the phosphorylation of STAT3 
over STAT1. It also docks well to the SH2-domain of STAT3 and has a potential to be developed as 
a STAT3-targeting drug. Other compounds act through a different mechanism(s), but are also 
plausible for chemical modifications and development, both as drugs and as molecular probes to 
identify novel targets important for the full oncogenic function of STAT3. 
Taken together, our findings demonstrate that the roles of STAT1 and STAT3 in cancer are not 
strictly determined, but are highly context-dependent. It appears that the IFN/STAT1 signalling can 
be both pro-apoptotic and pro-survival, whereas the oncogenic JAK/STAT3 axis can be targeted to 
induce cancer cell death. 
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1 INTRODUCTION 
In this section, I address the main concepts that are relevant for the papers included in the thesis. 
1.1 CANCER AS A PAYMENT FOR MULTI-CELLULARITY AND LONGEVITY 
 
Cancer is not a single disease, but a collective name for hundreds of diseases drastically 
different in their topology, clinical course, therapy response, and outcome.1 From the evolutionary 
point of view, cancer is a by-product and a consequence of the multicellular organisms development 
that have complex regulatory mechanisms of cell fate.2 Despite the intricate mechanisms of cell 
cycle and cell death regulation in higher animals, stochastically occurring mistakes do happen 
during the cell division. Normally, they get corrected by a DNA repair system, or a cell carrying a 
defect is eliminated.3 However, when odds are not in one’s favour, a cell with the damaged genomic 
information survives and passes the defect to the offspring cells. It creates a vicious circle of cell 
divisions that produce a lot of cells with an unrepaired DNA damage. The probability of a mistake 
leading to oncogenic transformation is proportional to the cell number and the lifespan 
of an organism (hence, the number of divisions). 
However, not all mutations lead to cancer development. The human genome is estimated to 
contain 6 billion base pairs. About one mismatch is generated per one cell division. That accounts 
for the estimated mutation frequency of about 10-5-10-7 per gene.4 Of note, the mutation frequency is 
not uniform across the genome and even throughout a chromosome.5 Firstly, it highly depends on a 
gene expression. Secondly, a gene location within a chromosome plays a role, as the genes at the 
chromosome ends tend to be more prone to mutation accumulation. It might be explained by 
nucleotide depletion and a shorter time these genes are in a complex with a DNA-polymerase and 
mismatch repair proteins.6,7  
Advances in sequencing have allowed the estimation of the mutation rate in absolute 
values. Y-chromosomes from two individuals with a common ancestor born 200 years ago and 13 
generations of faithful Y-chromosome passing from fathers to sons were sequenced. That summed 
up to about one mutation/ 3x107 base pairs and resulted in an estimate of about 100-200 new 
mutations per generation.8 Thus, the mutation frequency is much higher than the frequency of 
cancer development when  DNA repair systems and the immune system detection are in place. 
 
1.1.1 The acquired capabilities of cancer cells 
 
The common features shared by the majority of cancers regardless of their origin have been 
called the ‘hallmarks of cancer’.9 As the knowledge on the molecular basis of cancer deepened, the 
view of cancer hallmarks also progressed and new hallmarks have been added.10 Interestingly, 
following the publication of both reviews on the hallmarks of cancer, an avalanche of papers 
appeared suggesting yet new hallmarks of cancer. (e.g., cancer stem cells or intra-tumour pH).11,12 
This demonstrates that we still have a lot to learn regarding how cancer cells function. 
 
According to the most general and the most simplistic theory, all cancers can be described 
by the following acquired capabilities (hallmarks) that distinguish them from normal cells: 
 
• sustaining proliferative signalling; 
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• evading growth suppressors; 
• resisting cell death; 
• enabling replicative immortality; 
• inducing angiogenesis; 
• activating invasion and metastasis. 
 
Sustaining proliferative signalling and evading growth suppressors.  
 
Under normal conditions, a balance between proliferative and anti-proliferative signals 
directs the fate of a cell depending on the requirements of the environment. Genes involved in the 
regulation of proliferation in normal cells (proto-oncogenes) become oncogenes upon gain-of-
function mutations, amplification, or chromosomal re-arrangements that lead to a continuous 
proliferative signalling. For example, HER2 is a receptor Tyrosine kinase that is weakly expressed 
in normal epithelial cells but is overexpressed in several types of cancer.13 Ligands do not usually 
bind HER2 directly but they recognise specific sites at HER1, HER3, or HER4. HER2 functions as 
a co-receptor and exhibits a kinase activity only in a complex with other HER family members.14 
HER2-containing complex is preferred by many ligands because of its slow internalisation rate and, 
therefore, a prolonged response.15 Overexpressed HER2 spontaneously forms heterodimers with 
other HER-receptors, that results in the activation of the pro-survival PI3K/Akt and MAPK 
pathways without an external stimulus.16 Cells harbouring such a defect would normally be detected 
and eliminated through the p53-regulated cell death, but the cells with mutations in p53 alongside 
HER2 amplification will evade apoptosis and survive.  
This example demonstrates that (1) proto-oncogenes (e.g., HER2) can become oncogenes 
due to genetic changes; (2) tumour suppressor genes (e.g., p53) can become inactivated (through 
mutations, promoter methylation, etc.); (3) at least two genetic events are usually necessary to 
initiate uncontrollable cell proliferation and survival (at least in epithelial tissues).16 
Resisting cell death. Damaged or infected cells are normally eliminated through a 
programmed cell death. Despite the accumulated defects, transformed cells are able to avoid 
apoptosis and to prolong their lifespan. The tumour-suppressor p53 is the main inducer of the cell 
death upon stress: It stops the cell cycle and regulates apoptosis through both transcriptional and 
non-transcriptional mechanisms.17 Concurrently to p53 inactivation, the apoptosis evasion is 
ensured through the upregulation of anti-apoptotic proteins (e.g., Bcl2, Mcl1)18 or inhibitors of 
apoptosis (e.g., survivin).19 
Enabling replicative immortality. Following a certain number of cell divisions, non-
transformed cells enter a quiescent state and eventually undergo apoptosis. This phenomenon 
(‘Hayfliks limit’) has been correlated with the length of the telomeres, small signalling segments of 
DNA that become shortened with every cell division. Upon critical telomere shortening, a cell gets 
quiescent, enters a crisis state and undergoes apoptosis.20 A telomerase complex that restores the 
telomeres after each cell division is normally active in the early embryogenesis, and adult cells do 
not express it. To overcome the Hayflicks limit, the cells might overexpress a telomerase thus 
becoming virtually immortal. Apart from that, telomeres can get stabilised by special telomere-
binding proteins. Overcoming the Hayfliks limit is yet another strategy of cancer cells to evade 
physiological death.21 
Inducing angiogenesis. Cancer cells, even more so than normal cells, depend on the 
nutrients and metabolites that are transported by the vasculature.22 During embryogenesis, blood 
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vessels partially form de novo, and partially sprout into the growing tissues in response to pro-
angiogenic stimuli. Thus, the vasculature develops as an organism grows, and in a fully-grown 
organism blood vessels sprout only on demand (e.g., upon injuries) in response to the short-termed 
activation of pro-angiogenic factors. As both proto-oncogenes and tumour-suppressor genes 
regulate normal cell division, the balance of pro- and anti-angiogenic factors determines 
angiogenesis.20 A tumour is a growing organ that quickly gets hypoxic.23 That, together with an 
oncogenic stress, induces the expression of angiogenesis activators of (e.g., MMP-9,24 VEGF,25 
TGFβ26) and triggers ‘angiogenic switch’.27 An unbalance in the expression of angiogenesis-
regulating factors leads to the development of the disorganised vasculature with non-hierarchical, 
dilated, and highly permeable vessels.28  
Activating invasion and metastases. The terminal stage of tumour progression is the 
dissemination of tumour cells and the development of metastases that eventually kill a cancer 
patient. Dissemination is believed to begin with the epithelial-to-mesenchymal transition (EMT) in 
individual tumour cells. They upregulate mesenchymal transcription factors (e.g., Slug, Snail, 
Twist), become growth arrested, lose intercellular adhesion, and increase cell motility.29 Tumour 
cells together with the cells of the microenvironment actively remodel extracellular matrix (e.g., 
through secretion of the extracellular proteases of MMP family) to provide an access to the 
bloodstream.30,31 The abnormally fenestrated epithelium of tumour vessels facilitates the 
intravasation and dissemination of tumour cells.32 When in the blood stream, tumour cells require 
additional mechanisms of survival and protection from immune recognition. It has been shown that 
context-specific activity of PI3K/Akt pathway is instrumental for the survival of cancer cells both in 
the circulatory system and in a new site.33 Also, a distinct CD47 expression on disseminating cancer 
cells (that is absent in the primary tumour cells) was shown to protect tumour cells from the reactive 
lymphocytes.34 It is proposed that seeding occurs in specific niches of distant organs that have 
receptive microenvironment conditions allowing tumour cells to reside therein.35 Upon reaching 
such a niche, cells undergo mesenchymal-to-epithelial transition that is required to overcome a 
growth arrest.36 After some dormancy period, disseminated cells establish new microenvironment 
conditions suitable for their subsequent proliferation and growth.37,38 
Current treatment regimens are not efficient in eliminating metastases for several reasons. 
Firstly, resolution of the detection methods does not allow to detect a tumour at the stage when no 
disseminated cells are present.39 There is a view suggesting that tumour cell dissemination is not a 
late process (as was thought before), but might occur at early stages; thus, it is not possible to 
eliminate all cancer cells by the surgical removal of the primary tumour.40 Secondly, cells that have 
undergone EMT are rather resistant to treatment, that allows them to survive outside the primary 
tumour.41 Thirdly, a mutation profile of metastases only partially overlaps with that of the primary 
tumour cells; therefore, the treatment cannot be tailored according to the original tumour mutation 
status.42 Finally, we might lack sufficient knowledge and methods to detect metastases before 
disseminated cells overcome dormancy and start proliferating. 
It should be noted that apart from the purely genetic defects discussed above (i.e., 
aberrations in the protein coding genes) there are multiple additional layers of transcriptional, 
translational, post-translation regulations not mentioned here (e.g., epigenetic regulation, alternative 
splicing, miRNA regulation, lncRNA, SNPs, etc.) Also, it cannot be stressed enough that each 
cancer type has a unique pathogenesis where a complex interplay between different molecules 
orchestrates the final phenotype. 
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1.1.2 Cancer stem cells 
 
The simplest view appears to me undoubtedly to be that in an early stage of embryonic 
development more cells are produced than are required for building up the part concerned, 
so that there remains unappropriated a quantity of cells--it may be very few in number--
which, owing to their embryonic character, are endowed with a marked capacity for 
proliferation… The only point on which I lay stress is that the real cause of the subsequent 
tumour is to be sought in a fault or irregularity of the embryonic rudiment. (Julius 
Cohnheim, 1889) 
 
Similarities between ontogenesis and oncogenesis were noticed years ago. That gave rise to 
the cancer stem cell (CSC) theory of cancer initiation and progression. This view is akin to normal 
development and tissue regeneration, suggesting that there are few pluripotent cells within each 
tissue that can give rise to all differentiated cells within an organ and at the same time maintain 
themselves. Tissue-specific stem cells originate from even less specialised omnipotent cells that can 
give rise to virtually any cell type, while also sustaining their own pool through an asymmetric 
division. An intricate constellation of growth factors present in the environment43 tightly regulates 
each stage of division and differentiation.  
The analogy between normal and cancer stem cells was drawn from the observation that 
stem cells, in order to divide, temporarily activate proto-oncogenes and then return to the quiescent 
state until a further need. Research has found that not all tumour cells are equally tumourigenic 
when xenografted into immunodeficient mice.44 Taken together, these notions gave rise to a cancer 
theory claiming that there are, at least, two functional classes of cells within a tumour: one that 
could have lost its tumour-initiating capacity and forms the tumour mass and the other that can give 
rise to new tumours.  
The origin of cancer stem cells is debatable. They could, potentially, emerge from normal 
stem cells since they possess many of their features (e.g., resistance to apoptosis),45 which might be 
the case in some cancers.46 Since the mutation rate is highly dependent on the number of 
replications, and stem cells were estimated to have ≈100-fold lower mutation frequency than 
somatic cells. Therefore, the probability of a stem cell becoming a cancer stem cell is rather low.47 
An alternative theory suggests that after the malignant transformation, certain cells de-differentiate, 
gain the features of stem cells, and then divide asymmetrically to produce tumour mass.48 Also, 
cells with cancer stem cell-like properties can be induced by, for example, STAT3-mediated 
inflammation,49 as well as other factors in the existing tumour.50 It demonstrates that the pool of 
CSCs and orthogonal differentiation of cancer cells might not be terminal.51 
CSCs are the most resistant to any external stress and, therefore, they survive during the 
treatment and initiate a new tumour which then develops clonally.52 Presumably, the treatments at 
our disposal cannot  reach and affect cancer stem cells, that may explain tumour recurrence.53 
Therefore, CSCs targeting has high potential in anti-cancer treatment regardless of the cancer 
origin. Also, it is believed that CSCs might maintain their own microenvironment within a tumour 
that allows them to survive. Studying and manipulating the conditions of cancer stem cells micro-
niche can also be a treatment strategy by itself.54 
Overall, the existence of therapy-resistant cells adds to the complexity of tumour cells 
targeting. Identification of this cell population for research purposes is a tedious task, especially 
when we do not know exactly what we are seeking. However, as the knowledge about the biology 
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of CSCs accumulates, there are more and more studies that develop systems for anti-CSCs drugs 
screening.55 
 To summarise, there is profound evidence that cancer is a disease of the genome 
even though most cancer types are not inheritable. Diverse mechanisms regulate neoplastic 
transformation in different tissues, and the combinations of genetic alterations are impossible to 
count. The development of deep-sequencing methods allowed to look more closely at the 
mutational landscape in several cancer types, but the functional studies are still to be done to 
distinguish the meaningful information from the genetic noise. Overall, it is not doubted now that 
there will not be a single treatment to cure cancer, but there will be therapies and combinations of 
therapies to treat individual cancers. 
 
1.2 INTERFERONS (IFN) 
 
 
IFNs are a group of ancient cytokines exerting pleiotropic effects in an organism. They are 
naturally produced by cells in response to the danger-sensing patterns (e.g., infection). The 
discovery and the first phenomenological description of IFNs date back to 1957 when Isaacs and 
Lindenmann discovered the phenomenon of ‘interference’ with secondary viral infection is 
prevented within hours and even days after the primary infection.56,57 It was clear that a soluble 
factor was involved, since the treatment of the cells with inactivated virus led to the protection from 
a secondary infection with a replication-competent virus. This factor had extreme potency, as it was 
applied as a component of a crude cell extract and still had remarkable efficiency. It was not until 
about 20 years later that interferons were purified, and their effects were studied in more detail.58,59 
It became apparent that interferon is not a single substance but comprises several types, later 
denominated as type I, II, and III interferons. 
 Type I IFN includes IFNα1-12, IFNβ, IFNε, IFNκ, and IFNω; type II—only IFNγ, and type 
III—IFNλ1-4. The difference among the types of IFNs lies in the receptors they bind to, in the 
activating stimuli and, partially, the mediators of signal transduction.60 In the papers included in this 
thesis, we mainly worked with IFNα2a, and only a little with IFNβ (in paper II) and IFNγ (paper IV), 
therefore, I will mainly focus on type I IFNs. 
 
 
1.2.1 IFN-induced signalling 
 
 Type I IFNs signal through the cognate IFNα/β receptor that consists of IFNAR1 and 
IFNAR2 chains. Unlike many growth factor receptors, the IFN receptor complex does not have the 
kinase activity. Instead, IFNAR2 is constitutively associated with JAK1 in its cytoplasmic domain. 
Following IFN binding to the external domain of the receptor, the receptor subunits dimerise 
allowing JAK1 to phosphorylate the IFNAR1-bound kinase Tyk2. Next, JAK1 and Tyk2 get further 
activated by cross-phosphorylation and they, in turn, phosphorylate the intracellular part of the 
receptor complex to create docking sites for the SH2-domains of STATs and other signalling 
proteins.61  
Type I IFNs induce phosphorylation and homo- and hetero-dimerisation of virtually all 
STAT proteins, depending on the cellular context. The main transcription factor induced by IFNα is 
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ISGF3 that is a triple complex of pSTAT1, pSTAT2, and a DNA-binding protein IRF9. This 
complex binds to interferon-sensitive response elements (ISRE) in the promoters of target genes 
thus regulating their transcription.62 Apart from ISGF3, IFN also induces homo- and heterodimers 
of phosphorylated STATs that regulate the expression of a separate gene set through binding to the 
gamma-activated sequence (GAS).  
IFNγ binding of to its receptor complex leads to a similar cascade of events.  The receptor-
associated JAK1 and JAK2 cross-phosphorylate and activate cytoplasmic STAT1. Phosphorylated 
STAT1 homodimer is the main IFNγ-induced transcription factor that binds to the GAS elements in 
the gene promoters.63 Also, there are reports that, in special cases, IFNγ can induce ISGF3 
complex,64 phosphorylation of STAT3, and interaction with other transcription factors, thus 
providing a multifaceted response and a prerequisite for the signalling crosstalk.65  
There is some overlap between type I IFN- and type II IFN-induced genes. For example, 
IFITM1 can be induced by either as its promoter contains both ISRE and GAS  binding sites. There 
is also a subset of the genes induced exclusively by one or another (e.g., OAS2 promoter has ISRE, 
but no GAS, therefore, it can be induced only by type I IFNs).66  
 
1.2.2 Interferon-stimulated genes 
 
IFNs induce  500-2,000 genes depending on the cell type, treatment duration and the 
dosage.67 Knowledge about the functions of different ISGs is not homogenous. The exact 
mechanistic effects of all ISG products on viral clearance remain to be determined. However, some 
of the genes are relatively well-studied. Below, I will focus on the functions of some ISGs that are 
under study in this thesis. 
One of the best characterised genes induced by IFN stimulation is 2’-5’- oligoadenylate 
syntase (OAS 1-3 and RNase L). The function of these enzymes is to polymerise ATP into 2’-5’-
oligoadenylates. Proteins of OAS family members are almost non-detectable under normal 
conditions, but their expression is rapidly induced by viral dsRNA. 2’-5’-oligoadenylate binds to the 
monomeric RNase L causing its dimerisation and activation. In turn, this leads to the enzymatic 
degradation of the viral and host RNAs into small ssRNAs.68,69 The products of RNase L can be 
further sensed by the cells and induce further production of IFN.70 
The mechanism of action of an ISG product IFITM1 is less clearly understood. It has been 
shown that IFITM1 protein can localise close to the intracellular vesicles, forming exosomes, the 
Golgi apparatus, and the plasma membrane.71 Unlike OAS, it is expressed in the cells at a basal 
level and it is involved into cell adhesion. IFNs further induce IFITM1 that provides protection 
from a wide range of viruses.72 IFITM1 has also been shown to induce p53-dependent senescence in 
the cells.73 In tumours, the role of this protein and other IFITM family members is not as clear.  
Elevated levels of IFITM1 expression have been associated both with drug resistance and treatment 
response in different systems.74-77 There is also a report that shows that increased expression of 
IFITM1 leads to aggressive tumour phenotype.78 
IFI27 was first cloned from the breast cancer cell line MCF7 and was immediately 
associated with tumourigenesis.79 Further investigations mostly confirmed the initial finding, as 
IFI27 (or p27) was identified by multiple gene expression arrays in conjunction with aggressive 
forms of cancer, treatment resistance, and the regulation of the epithelial-mesenchymal transition in 
various cancers.80-82  
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1.2.3 Alternative signalling pathways induced by type I IFNs 
 
The JAK/STAT pathway was discovered and first characterised as the main mediator of the 
IFN-induced response. Currently, there is abundant evidence that IFNs also stimulate other 
pathways. The PI3K pathway was shown to be activated alongside with the JAK/STAT signalling 
and was found essential for the adequate transcriptional response. From the mechanistic point of 
view, it has been found that type I IFNs induce phosphorylation of IRS1 and IRS2 adaptor proteins 
that bind the activator subunit of PI3K p85 through the SH2 domains.83,84 p85 activation induces the 
catalytic subunit of PI3K p110 followed by the signal propagation to AKT, mTOR and, eventually, 
to several transcription factors (e.g., NF-κB, AP1, etc.) Simultaneously, the negative feedback 
regulation of PI3K is activated that efficiently shuts down the IFN signal.85,86 To summarize, IFNα 
induces JAK-dependent phosphorylation of the IRS proteins that trigger the PI3K signalling 
cascade. This process is independent of the STAT phosphorylation.87  
Some reports show that IFNγ also induces PI3K without the involvement of the 
phosphorylated IRS proteins. The PI3K pathway activity is required for the phosphorylation of 
STAT1 on Ser727 that is performed by a PI3K-activated kinase PKCδ and is necessary for the full 
transcriptional activity of the STAT1 dimer.88,89 
A separate arm of the PI3K signalling goes through mTOR. This protein is rapidly 
phosphorylated downstream of the PI3K, which activates it and leads to the phosphorylation of 
p70S6 kinase.90 p70 targets S6 subunit of ribosomes, thus stimulating translation through the 5′-
terminal oligopyrimidine tract. Additionally, mTOR/p70S6K activation leads to the deactivating 
phosphorylation of the transcriptional repressor 4EBP1 on several serine and threonine residues. 
This event leads to the release of the 4EBP1 from the inhibitory ElF4E  protein and initiates 
translation.91 
Ras/MAPK pathway is activated by the type I IFNs as well.92 The adaptor protein CRKL is 
phosphorylated by Tyk2, which leads to the phosphorylation of a small GTPase RAP1. It further 
signals to MAPKKK and, ultimately, to p38, which is of particular importance for the antiviral 
defence.93,94 It has been shown that p38 participates in the phosphorylation of STAT1 on Ser727,95 
but this fact was later debated.96 The activities of the MEK/Erk and the JNK arms were also 
registered in response to IFNs. As was earlier shown by the study from our lab, JNK is important 
for the activation of the mitochondrial proteins Bak and Bax that participate in the IFNα-induced 
apoptosis.97 
 
1.2.4 The biological effects and clinical use of IFNs 
 
IFNs appeared early in the evolution of vertebrates, that indicates their importance in 
homeostasis. The main function, as was discussed above, is the control and eradication of 
infections. IFNs execute the first non-specific line of the defence against pathogens by inducing the 
expression of ISGs.  Apart from the direct antiviral effect, IFNs also stimulate the immune system 
by activating a number of the immune cells (e.g., natural killer cells (NK cells) and macrophages) 
and by enhancing the antigen presentation through the upregulation of MHC class I expression. 98,99 
NK cells activation was found to be a prerequisite for efficient anti-tumour immunity.100. It has also 
been noticed that IFNs induce a cell cycle arrest and, as a consequence, inhibit cell proliferation by 
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prolonging almost all phases of the cell cycle.101,102 Moreover, IFNs have a direct pro-apoptotic 
effect on cancer cells independently of the cell cycle arrest.103,104 effect on cancer cells by inducing 
their cell death independently of cell cycle arrest. Due to these effects, recombinant IFNs were tried 
in the treatment of viral and oncological diseases.  
In 1986, the FDA approved IFN for the treatment of hairy cell leukaemia, and later for 
multiple sclerosis, follicular lymphoma, chronic hepatitis B and C infection, and AIDS-related 
Kaposi sarcoma. IFNs were also evaluated for the treatment of other types of cancer, but their wide-
spread usage was limited by the narrow therapeutic window. The side-effects of the IFN treatment, 
such as muscle and back pain, depression, anorexia, congestion, and flu-like symptoms, are 
common for almost 50% of the patients. The mechanisms of these effects are poorly understood; 
therefore, there is a limited opportunity to relieve them.105,106 However, when used in sufficiently 
high doses, the IFN treatment is very beneficial for the patients.103,107 Significant side effects in the 
absence of predictive biomarkers make oncologists reluctant to use IFNs in their practice.108,109 
Overall, considering all cancer types, the gain of IFN treatment is rather moderate due to dose 
limitations, but there is a high potential which might be realised by novel intra-tumour delivery 
methods and the development of robust criteria for the clinical benefit of this treatment. 
 
1.3 IL6 SIGNALLING IN CANCER 
 
Originally, interleukin-6 (IL6) was discovered as a soluble factor produced by T-cells, 
which stimulated B-cells to terminal differentiation and immunoglobulin production.110 IL6 is 
secreted mainly by the immune cells (lymphocytes, monocytes, macrophages, etc.) as well as some 
non-immune cells (fibroblasts, endothelial cells, keratinocytes, etc.). The IL6 production can be 
stimulated by some cytokines and growth factors (IL1, TNF, PDGF, etc.) as well as viral and 
bacterial infections. IL6 signalling starts from the binding of IL6 to its receptor. Immune cells 
usually express a transmembrane IL6-R, whereas other cells mostly express a soluble form of the 
receptor (sIL6-R) produced either by the proteolytic cleavage of the transmembrane receptor or by 
the alternative splicing of the IL6-R gene. There is no catalytic domain in the IL6-R, therefore IL6 
binding to either transmembrane or soluble receptors is followed by the association with another 
transmembrane receptor subunit gp130. The signalling triggered by IL6 binding to its membrane 
receptor is commonly referred to as ‘a classical pathway’, whereas IL6 binding to the sIL6-R is 
referred to as ‘a trans-signalling pathway’. The difference between the two pathways is in their 
sensitivity and even in the ultimate effect. 111,112 
After the formation of the IL6/IL6-R/gp130 or the IL6/sIL6-R/gp130 complex, several 
signalling pathways are induced: Ras/MAPK triggers the cascade leading to the transcription of 
acute phase genes while JAKs recruitment leads to the activation of STATs and PI3K, both 
stimulating the expression of the genes involved in complex immune reactions.113 
Dysregulation of the IL6 pathway leading to sustained signalling has been associated with 
several diseases. Firstly, it leads to autoimmune diseases in the nervous, cardiovascular, and 
respiratory systems and causes the immune-mediated kidney and colon diseases.106 Secondly, 
increased production and continued IL6 signalling contribute to various steps in cancer progression 
through the cell proliferation induction, mediation of the tumour cells-stroma interactions, the  
epithelial-mesenchymal transition stimulation, angiogenesis, and drug resistance.114,115 As an 
example, mammospheres of normal breast epithelium exposed to IL6 showed signs of 
transformation and increased proliferation.116 Also, constitutive expression of IL6 in a non-invasive 
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MCF7 cell line led to the downregulation of E-cadherin, and the upregulation of vimentin, N-
cadherin, Snail and Twist, and promoted increased metastasising capacity of the cells.117  
The first drugs targeting the IL6 pathway were the humanised anti-IL6 antibodies. The 
trials of tocilizumab, one of the anti-IL6 drugs, showed the efficiency of the IL6 blockage in active 
rheumatoid arthritis (RA) even as a monotherapy,118 and even higher efficiency in combination with 
anti-inflammatory drugs. Other biologics tested for the inhibition of the IL6 signalling include 
modified anti-IL6 antibodies olokizumab,119 sirukumab,120 siltuximab;121 anti-IL6R antibodies such 
as sarilumab;122 and drugs targeting IL6-IL6-R complex like gp130-Fc.123.124 The blood levels of C-
reactive protein (CRP) are used to assess the effect of the drugs in auto—inflammatory diseases.125 
Overall, IL6 targeting was successful in the treatment of RA, which encouraged investigating the 
anti-IL6 drugs in cancer. 
Several IL6-targeting drugs were in clinical trials for the castration-resistant prostate cancer, 
the metastatic colon cancer, and some other advanced solid tumours. Mostly, the side-effects were 
mild and tolerable. However, the clinical response was not significantly different compared to 
placebo.126 Similarly, the addition of an IL6-targeting drug to bortezomib in the treatment of 
multiple myelomas did not improve the clinical outcome of patients.127 CRP levels were 
prominently downregulated under the treatment; however, this did not correlate with the anti-
tumour efficacy of the drug, unlike in the anti-inflammatory effect in RA.127 
In summary, biological drugs against IL6 are efficiently used in the treatment of some 
autoimmune disorders. The use of anti-IL6 drugs in cancer has not been successful yet. A possible 
reason is the dose limitations which do not allow efficient inhibition of IL6 signalling in tumours. 
Another reason might be the substitution of the IL6 signalling by other cytokines from the IL6 
family. Currently, the efforts are directed towards the development of a non-antibody drug to 
decrease the immunogenicity and to improve the affinity to IL6. While clinical testing is rather 
straightforward in RA, testing anti-IL6 drugs in cancer is more challenging and time-consuming. 
 
 
 
1.4 SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTION (STATS) 
 
The family of signal transducers and activators of transcription comprises seven family 
members: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6, each encoded by a 
different gene. This group of transcription factors was discovered in conjunction with the studies on 
the IFN-induced signalling as it was found that they were the main mediators of the IFN signal to 
the nucleus. Later, it became apparent that many of the cytokines and growth factors also passed 
their signals through STATs. Moreover, STATs are in the centre of the Tyrosine kinase activity 
within a cell; therefore, they mediate multiple fundamental processes in cell homoeostasis.128  
All seven STATs share the same five-domain structure: an N-terminal domain, a coil-coiled 
domain, a DNA-binding domain, an SH2 domain, and a C-terminal domain (illustrated in Figure 1). 
The STATs are similarly activated: upon the external signalling molecule binding to the 
corresponding receptor, STATs get phosphorylated in the cytoplasm by JAKs, SRC, or other 
tyrosine kinases. A crucial phosphorylation position is a tyrosine residue located within the 
transactivation domain. Some STATs (STAT1, STAT3, STAT4, STAT5a, and STAT5b) have an 
additional Serine phosphorylation site located in the close proximity to this Tyrosine residue. The 
primary event in the STAT-activation is the Tyrosine phosphorylation, whereas Serine 
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phosphorylation is secondary. It was shown that the Serine phosphorylation is required for the full 
transcriptional activity of STATs and for some of their non-transcriptional functions.129  
 
 
  
Once activated, STATs form homo- and heterodimers through the reciprocal interactions 
between phosphor -Tyrosine residues and the SH2 domains. In the dimerised form, STATs expose 
their nuclear localisation signals and are actively transported through the nuclear pore complex by 
importins. In the nucleoplasm, the STAT dimers recognise their binding motifs at DNA in the gene 
promoters, thus regulating the gene transcription. Nuclear phosphatases (e.g., TC45) 
dephosphorylate STATs released from DNA, and they are returned to the cytoplasm by exportins.130 
Also, STATs induce the transcription of their negative regulators suppressors of cytokine signalling 
(SOCS)131 and other cytoplasmic phosphatases, thus providing a dynamic mechanism for the 
feedback regulation. 
Nuclear import of STAT3,132,133 STAT5,134,135 and STAT6136 does not depend on their 
phosphorylation status, causing these proteins to shuttle continuously between the nucleus and the 
cytoplasm. Recently, it has been shown that unphosphorylated STATs are not latent factors as was 
thought before, but instead, they have a unique transcriptional activity or function as part of a larger 
transcriptional complex.137  
Although there is a high similarity between the amino acid sequences of the STATs, each of 
them mediates different functions depending on the context. Despite the fact that the general 
activation principle is shared by all STATs, the degree of specificity is conferred by the activating 
kinases, interactions with specific importins and transcription factors, and differential affinity to 
DNA sequences. Below, I will try to outline briefly some specific functions of STATs and their 
involvement in cancer and other diseases. 
 
1.4.1 STAT1  
Activation of STAT1 by IFNs leads to a massive multi-level immune response directed 
towards clearance of viral infection.138 STAT1 deficiency causes increased susceptibility to 
pathogens due to abrogated IFN signalling as well as through independent mechanisms.139-141 Also, 
mice lacking STAT1 are more prone to tumour development than wild-type animals, suggesting a 
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Figure 1. (A) The general domain structures of STAT1, STAT2 and STAT3. 
Phosphorylation sites in the transactivation domain are marked (B) The crystal structure 
of a STAT3 protein, domains are designated (the courtesy of B.Page)  
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tumour suppressive role of STAT1. The role of STAT1 in cancer is described in detail below in the 
corresponding section. 
 
1.4.2 STAT2 
STAT2 was discovered as a participant in the IFN-induced signal transduction which 
remained its only known function for decades. Type I IFNs activate it through the phosphorylation 
on a Tyrosine 680 residue. Afterwards, STAT2 forms heterodimers with other STATs. The roles of 
STAT2 homodimers and some of the heterodimers are not well understood. The well-studied 
complex containing STAT2 is ISGF3 (a triple complex of IRF9, STAT1, and STAT2). STAT1 and 
IRF9 provide DNA binding of the ISGF3 complex, whereas STAT2 recruits transcriptional 
enhancers. As described above, ISGF3 mainly regulates antiviral effects of type I IFNs through 
regulation of the genes containing ISRE in their promoters.142 It has been found that type I IFNs can 
propagate the signal also in the absence of STAT1 through an alternative complex containing a 
STAT2-homodimer and IRF9.143,144 Since the DNA-binding affinity of this complex is considerably 
lower than that of ISGF3, it was suggested that elevated levels of STAT2 and IRF9 or both might be 
required.145 It was also shown that the STAT2-IRF9 complex provides a prolonged transcription of 
the the ISGs that is particularly important for eliminating certain pathogens, such as L. 
pneumophila, Dengue virus, paramyxovirus, and so forth.146,147 On the other hand, the STAT2-IRF9 
complex might act as a reserve mechanism of the innate immune system in case viruses interfere 
with the function of STAT1. Recently, it was demonstrated that Zika virus expresses a ubiquitin 
ligase specifically targeting STAT2 and, in this way, preventing the formation of the normal IFN-
induced virus clearance.148 Overall, STAT2 appears to play an important role in mediating immune 
response, not only through the classical ISGF3 complex.  
The direct role of STAT2 (outside its involvement in the function of the immune cells) in 
tumour development and tumour progression is less clear. Some evidence suggests that STAT2 
might be involved in the malignant transformation by regulating the production of IL6. This 
conclusion was drawn from the experiments on the STAT2-null mice that had decreased serum 
levels of IL6 comparing to the wild-type animals. The STAT2-null mice were also protected from 
the formation of colon tumours.149 On the other hand, increased STAT2 staining was more 
frequently detected in cervical cancer specimens than in the non-cancerous and pre-cancerous 
lesions.150 Some studies also point out at the involvement of STAT2 in drug resistance through the 
regulation of ISGs.151 Taken together, the role of STAT2 in cancer remains controversial and is 
most probably cell-context dependent. 
 
1.4.3 STAT3 
STAT3 was first discovered as a factor interacting with the promoters of acute-phase response 
genes upon the IL6 stimulation of hepatocytes. It was later shown that it had a structure similar to one 
of the earlier described transcription factor STAT1.152 Apart from IL6, STAT3 is activated in response 
to other cytokines that signal through the gp130 receptor (e.g., IL1, IL5, LIF), IFNs (mainly type I), 
and multiple growth factors (e.g., EGF, HGF, FGF), as illustrated in Figure 2.153 The STAT3-
regulated genes were found not to be restricted to acute-phase response regulators but turned out to 
cover a wide range of genes important for development, survival, and homoeostasis of an organism.154 
Moreover, due to its infamous involvement in the pathogenesis of cancer and autoimmune disorders, 
STAT3 became one of the most studied STAT family members.  
 20 
 
Immune system 
 
The STAT3 transcriptional function in the immune cells is, probably, best described as a 
double-edged sword as it is involved in both immune suppression and immune activation. Under 
normal conditions, STAT3 is the main transcription factor that responds to epithelial G-CSF during 
emergency granulopoiesis (e.g., in response to infections).155 It directly regulates CEBPβ and c-myc 
expression in the granulocyte precursors in the bone marrow.156,157 It was also observed that STAT3 
plays a crucial role in the development of dendritic cells: It inhibits their maturation.158-160 In 
phagocytes, STAT3 limits the inflammatory response through downregulation of the signalling from 
TLRs: Mice lacking STAT3 in the myeloid compartment spontaneously develop enterocolitis.161 In 
the adaptive immunity, STAT3 is also involved throughout. For example, it is required for the early 
stages of pro-B-cells development and for the IgG production in mature B-cells.161 T-cells also require 
STAT3 for survival (independently of the regulation of Bcl2) and also for the differentiation of Th17 
lineage through the transcriptional regulation of RORγ and RORα,162 IL23R and IL17R.163  
Given the important role the immune system plays in cancer, the role of STAT3 in the 
malignant transformation and the tumour progression is also intricate. It was proposed that 
IL6/STAT3 signalling contributes to the induction of the immune tolerance. For example, STAT3𝛽-
bearing tumours were significantly diminished in their size comparing to STAT3 wild-type tumours in 
the immune-competent mice. Also, STAT3 knockdown in the tumour cell compartment led to the 
immune cells infiltration into the tumour site and a massive production of pro-inflammatory cytokines 
and chemokines that induce the anti-tumour immune response.164 STAT3 deletion in a different subset 
of the immune cells led to an increase in the anti-cancer immunity, pointing out that the constitutive 
STAT3 activity in some immune compartments may contribute to the local suppression of the anti-
tumour immunity.165  
It was also demonstrated that a signalling circuit between tumour cells and the cells of the 
microenvironment leads to continuous expression of growth factors and immunosuppressive cytokines 
that not only activate STAT3 during their signalling, but also their expression is directly regulated by 
STAT3. For example, myeloid cells-derived VEGF binds to its receptor and induces STAT3 
phosphorylation and dimerisation followed by nuclear translocation of STAT3 and its binding to the 
promoter of VEGF.166 Similarly, IL6 signalling through the gp130 receptor utilises STAT3 and 
regulates its own expression.167 Apart from the increased secretion of immunosuppressive factors, it 
was shown that increased STAT3 activity interferes with the maturation of dendritic cells at the 
tumour site, thus making them incapable of efficiently presenting tumour-cell antigens.168 Also, 
STAT3-regulated expression of IL10 and TGF𝛽 in the immune cells leads to an increase in the 
population of Treg cells within a tumour that provides an additional level of immune tolerance.169-171 
Taken together, the paracrine interaction between tumour and immune cells in the stroma reciprocally 
regulate constitutive signalling activity necessary for the tumour cells proliferation and the 
suppression of the immune-mediated cell death. 
On the other hand, it is also well-documented that STAT3 promotes inflammation in 
epithelial tissues, thus supporting tumourigenesis.172 One of the described mechanisms involves 
interaction with the RelA subunit of NF-kB that leads to the repression of its transcriptional activity 
and inhibition of the Th1-mediated anti-tumour immune response. Other mechanisms include 
stimulation of IL6 expression by NF-kB, strong upregulation of the pro-tumourigenic genes by a 
STAT3-NF-kB complex (when STAT3 and NF-kB binding sites are adjacent in a promoter) and 
others that include multi-layered interactions with NF-kB.173-175  
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To summarise, STAT3 is an important transcription regulator in almost all subsets of immune 
cells. It participates in both immune suppression and immune activation, depending on the context. Its 
activity is controlled under normal conditions to provide optimal immune response, but cancer cells 
take advantage of the immune cells in the tumour site by engaging them in a continuous STAT3-
dependent circuit of signalling. Inhibition of STAT3 is believed to be beneficial not only to induce 
apoptosis directly in cancer cells addicted to it, but also to inhibit the STAT3-mediated inflammation 
or to induce anti-tumour immune response through the modulation of the resident immune cells the 
activity (a ‘bystander effect’).176  
 
 
Reproduction and early development 
 
For a long time, physiological functions of STAT3 were difficult to study using knockout 
mice since ablation of STAT3 led to early embryonic lethality (unlike any other STAT members). 
Careful investigation of the phenotypes upon conditional STAT3 deletion in different compartments 
of the female reproductive system revealed that STAT3 is expressed throughout from oocytes to the 
cells of the uterus. The leptin/STAT3 signalling was found to be involved into oocyte polarisation.177 
Surprisingly, though, oocyte depletion of STAT3 did not affect the fertilisation rate in mice. 
Conversely, the conditional deletion of STAT3 from the stromal compartment of uteri led to the 
reduced litter size due to abnormal placenta formation and the increased frequency of fetal 
resorptions.178 IL6 and STAT3 were also detected in spermatozoa, and the STAT3 inhibitor V 
impaired their motility.179 Since spermatozoa were mostly transcriptionally inactive and also because 
STAT3 localised outside their nuclei, it was assumed that STAT3 is important for the regulation of the 
motility through a non-transcriptional mechanism.180 Later, it was found that STAT3 regulated the 
mitochondrial activity of spermatozoa through a non-transcriptional mechanism.179 
Apart from its function in germ cells, STAT3 was found to be involved in the maintenance 
and differentiation control of stem cells.181,182 It gets phosphorylated by LIF in the four-cell embryo 
developmental stage and maintains the inner cell mass cell lineages through the transcriptional 
regulation of OCT4 and NANOG.183 In the context of the stem cell regulation during embryogenesis, 
STAT3 is indispensable. 
 
Mammary gland involution 
 
Another physiological function of STAT3 is the induction of the caspase-independent, 
lysosome—mediated cell death in response to LIF and OSM during mammary gland involution after 
lactation.184,185 Conditional deletion of STAT3 in the mammary epithelium causes significant delays in 
post-lactation regression, especially when abolished at the initiation stage of the involution.186 It was 
shown that during the first 24h of involution, Prolactin/STAT5 signalling ceases while the LIF/STAT3 
cascade increases its intensity. Proposed mechanisms of the STAT3 involvement in the lysosome-
mediated cell death encompass activation of cathepsins expression, repression of serine protease 
inhibitor 2A (Sip2a), and also a less understood process of the phenotypic switch in the mammary 
epithelium cells from the secretion to the non-professional phagocytosis of milk fat globules.185 The 
latter provides triglycerides that are hydrolysed to free fatty acids in lysosome-like vacuoles resulting 
in permeabilisation of their membranes and leakage of the cathepsins into the cytoplasm that 
concludes the cell death process.187 Transcriptional analysis of the STAT3 target genes in the 
mammary epithelium showed upregulation of cathepsin B and cathepsin L, as well as of the pro-
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inflammatory genes that are believed to contribute to the phenotype switch of the epithelial cells.188,189 
Taken together, STAT3 appears to play an important role in the induction of cell death in the 
mammary gland. Supposedly, a similar mechanism might be involved in other hormone-dependent 
cases of cell death, which remains to be investigated further.  
 
Cardiovascular system 
 
STAT proteins were found to play important roles in the function of the heart. All STATs are 
expressed in the heart; dysregulation of each STAT family member leads to a distinct phenotype that 
can be correlated to specific cardiomyopathies.190-192 Physiological and pathological remodelling of 
the myocardium in response to some stress (e.g., pregnancy, exercise, infarction, infections, etc.) 
initially have similar mechanisms. However, some types of stress lead to irreversible remodelling that 
is destructive for the function of the heart. STAT3 appears to contribute to both these processes and is 
believed to coordinate the fine balance between the normal and the pathological remodelling by 
regulating the expression of secreted factors that allow communication between different cell 
types.191,193 The cardiomyocyte-specific knock-in experiments showed that STAT3 regulates the 
expression of a pro-angiogenic factor VEGFA that promotes vasculogenesis and increases vascular 
permeability.194 VEGFA is induced in the heart in response to stress by, for example, the ischemia-
induced cytokines IL6 and EPO. G-CSF leads to the STAT3-dependent survival of the 
cardiomyocytes and increases capillary density during the myocardial infarction through mediation of 
the cardiomyocyte—endotheliocyte paracrine communication.195 The cardiomyocyte-restricted 
STAT3 knockout showed that male animals have an increased rate of cardiac fibrosis and the heart 
failure towards the older age.196 Female mice developed heart failure during pregnancy: in response to 
uncontrolled oxygen stress (normally relieved by PGC1α and MnSOD in a STAT3-dependent 
manner), cathepsin D was released from the cells, thus inducing the cell death and the degradation of 
capillaries.197-199  
STAT3 is also involved in the paracrine communication between cardiomyocytes and cardiac 
fibroblasts that is important for maintaining the optimal structure and condition of the extracellular 
matrix (ECM). STAT3 downregulates the expression of ECM components by cardiomyocytes that is 
necessary for efficient vascularisation after injury.200 At the same time, it also promotes survival, 
proliferation, and the ECM synthesis in fibroblasts that lead to fibrosis if not properly regulated.200,201 
Overall, STAT3 appears to play a complex role in maintaining heart homoeostasis and 
response to injury. Importantly, an increase in STAT3 levels in the heart triggers hypertrophy and 
inflammation,202 whereas diminishing STAT3 expression below certain threshold leads to heart 
failure—a phenotype to be aware of upon treatment of cancer patients with targeted therapies.203 
 
Central Nervous System (CNS) 
 
STAT3 expression in adult CNS is relatively low compared to other systems. The highest 
expression is observed during early embryogenesis and it gradually declines during the development 
and maturation.204 STAT3 expression in the adult brain is mostly restricted to neural stem cells where 
it regulates their proliferation and neuronal differentiation in response to glia-secreted cytokines (e.g., 
IL15, leptin, CNTF, LIF, etc.). Importantly, neurogenesis and neurite outgrowth in adults are 
dependent on the JAK/STAT3 signalling and cannot occur in the absence of it.205,206 Additionally, 
STAT3 is expressed in the gonadotropin-releasing neurones in the hypothalamus where they are 
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involved in the expression of sex hormones. Inhibition of the LIF/CNTF/STAT3 signalling leads to 
hampered reproductive development and sexual behaviour in rodents.207  
JAK2 and STAT3 were found to be important for the hippocampal synaptic plasticity.208 
Using JAK inhibitors, it was shown that the JAK2/STAT3 pathway regulates the expression of certain 
neurotransmitter receptors (e.g., GABA,209 NMDA,210 muscarinic acetylcholine146). Additionally, 
STAT3 regulates NMDAR-dependent long-term depression in the post-synaptic density, in this way 
also contributing to synaptic plasticity. For this function STAT3 seems to act independently of its 
transcriptional function.208,210  
Since STAT3 is involved in the regenerative processes in the brain, its activity is transient. As 
in other systems, defects in its activity regulation lead to pathological conditions such as brain 
inflammation and impaired neural and glial survival. Consequently, abnormal STAT3 signalling is 
frequently detected in the CNS diseases of different aetiology (e.g., brain cancer,211 epilepsy,212 
Alzheimer’s disease).213 
  
Non-transcriptional functions of STAT3  
 
Most of the studies on the function of STAT3 investigated its transcriptional effects on gene 
expression (similarly to other STAT proteins) that occurs through direct binding of the tyrosine—
phosphorylated STAT3 dimers to the promoters of target genes. In recent years, it was found that 
STAT3 also regulates gene expression in an un-phosphorylated form (U-STAT3) and even without a 
direct contact with chromatin. For example, U-STAT3 was found to be transported to the nucleus in a 
complex with NF-kB that regulates expression of certain genes.214,215  
An example of an outside-of-the-nucleus function of STAT3 is its activity in mitochondria 
(mitoSTAT3).216 It was found that STAT3 depletion in cardiomyocytes led to impaired function of 
complex I and II of the electron transport chain. It resulted in cell damage through excessive 
production of ROS.217  
Also, there is an indication that mitoSTAT3 is involved in the metabolic rewiring of cells by 
skewing their energy production towards glycolysis early in cancer development.218 MitoSTAT3 was 
found to be Ser727 phosphorylated independently of Tyr705 phosphorylation, and its deregulation 
was found to be involved in the oncogenic transformation in several cancer types.181,216 
 Overall, accumulating evidence suggests that non-nuclear STAT3 plays an important role in 
cellular respiration and metabolism. Therefore, design of STAT3 inhibitors for cancer therapy cannot 
be solely focused on the function of STAT3 as a transcription regulator.219 
 
STAT3 in cancer 
 
Since overexpression and activating mutations of multiple growth factors or their receptors or 
both are common in cancer, constitutively activated STAT3 is frequently detected in several cancer 
types. Considered a ‘non-classical’ oncogene, STAT3 regulates the expression of genes contributing 
to tumour progression at different levels.220 The target genes include anti-apoptotic, pro-survival, pro-
proliferation, and pro-invasion genes, many of which are recognised oncogenes.221 Since these genes 
are important for the very basic cell functioning; they are regulated by STAT3 in conjunction with 
other transcription factors, thus providing relative specificity of the response to different stimuli. 
STAT3-dependent regulation of the targets named above is well-studied in different systems. I will 
focus on the recently identified STAT3 functions implicated in carcinogenesis. 
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STAT3 conveys signals from multiple ligands, therefore, it can be partially accountable for 
the resistance to targeted therapies when more than one pro-survival pathway is involved. Apart from 
that, it has been shown in the example of Erlotinib, that cells activate STAT3 as a feedback 
mechanism to protect themselves from the cell death upon prolonged treatment.222 STAT3 activation 
occurs through the secretion of many STAT3-activating cytokines (e.g., IL6, IL10) upon the exposure 
of the cells to the drug. In a similar manner, the increased expression of STAT3 protects HER2+ 
breast cancer cells treated with Trastuzumab during a prolonged period.223 Overall, acquired resistance 
to several of the targeted therapeutics is often mediated through a feedback STAT3 activation.224 
The role of STAT3 in metastases was also convincingly demonstrated.225 Recently, STAT3 
hyperactivity in the immune cells has attracted much attention. It was shown that tumour-associated 
immune cells can prepare a new site for tumour dissemination by locally producing 
immunosuppressive cytokines and inducing immune tolerance towards cancer cells.226  
Lastly, STAT3 was found to be involved in the maintenance of cancer stem cells. Similar to 
its role in maintaining the ESC, LIF and IL6 mediate activation of STAT3 and suppress 
differentiation. CSCs are thought to account for the failure of the many cancer treatments, as they 
can tolerate the majority of the drugs and re-populate the tumour site hypothetically from a single 
cell.227More details about CSCs can be found in the introductory chapter. 
To summarise, STAT3 is an important regulator of many cellular events. Its activation is 
tightly controlled by different mechanisms to provide timely and adequate response. Once a 
dysregulation occurs, STAT3 can become a central knot of the tumour cell signalling. Therefore, 
targeting STAT3 holds promise for the improved therapy response and longer remissions in 
patients. 
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Figure 2. Schematic depiction of pathways that lead to the activation of STAT proteins. 
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1.4.4 STAT4  
This STAT family member is primarily expressed in T-cells and plays an important role in 
their differentiation and proliferation in response to IL12. Its activation occurs through IL12 binding 
to IL12R𝛽1 and IL12𝑅𝛽2 and a classical cascade of phosphorylations with the involvement of 
JAK2 and Tyk2. Without stimulation, Th1 and Th2 cells express low levels of the transcriptionally 
inactive STAT4. In response to IL12, the STAT4 dimer regulates the expression of the IL12-
responsive genes through a GAS element.228  STAT4 activation happens mainly in the Th1 cells, 
causing them to secrete IFN𝛾.229 Mutations and polymorphisms in STAT4 lead to autoimmune 
diseases (e.g., systemic lupus erythematosus, RA)230 and are associated with the spontaneous 
clearing of the viral infections (e.g., HBV infection).230 According to the reports in cancer, the 
IL12/STAT4 axis loss led to poor outcome in the hepatocellular carcinoma.231 On the other hand, 
metformin treatment led to the downregulation of IL22/STAT4 signalling in a mouse model of 
hepatocellular carcinoma. This treatment was associated with the cell death and tumour 
shrinkage.232 Similarly, chemotherapy led to the STAT4 protein degradation in lymphoma patients, 
but the outcome of the STAT4-loss is not clear.233 Overall, the role of STAT4 was studied mostly in 
the autoimmune diseases; its role in cancer is not fully established. Clearly, the STAT4 gene has 
multiple polymorphisms that may differentially affect its functionality and lead to different 
phenotypes.  
 
1.4.5 STAT5a and STAT5b 
STAT5a and STAT5b (STAT5) are coded by different genes in chromosome 17 and are 
located in the same locus as STAT3. The difference between STAT5a and STAT5b lies mainly 
within their C-termini that have 20 unique amino acids for STAT5a and 8 for STAT5b.234,235 
STAT5a and STAT5b have both redundant and non-redundant functions. Both of them regulate 
gene transcription through the GAS-site binding. STAT5a has most transcriptional activity when it 
is in a tetrameric form, whereas STAT5b shows high affinity to DNA as a dimer.  
Historically, STAT5a was discovered as a prolactin-responsive transcription factor in the 
mammary epithelium. Later, it was shown that numerous cytokines (such as IL3, IL5, IL2, IL7) and 
growth factors (e.g., GH, PRL, Epo) can activate STAT5a.236 On the other hand, STAT5b was 
found in the muscle and liver tissues and seems to have a distinct function in the body growth.237 
Consistent with the tissue-specific expression, the knockdown of STAT5a and STAT5b in mice led 
to different phenotypes. STAT5a k/o led to a lack of mammary gland development and 
differentiation during pregnancy;238 STAT5b-/- mice showed body growth abnormalities and liver 
dysfunction.239  
STAT5 is necessary for the lineage differentiation in the mammary gland and the 
hematopoietic system.238,240,241 Consequently, an abnormal activity of STAT5 can be most often 
seen in breast and blood malignancies. In the mammary gland, STAT5 is necessary for the 
differentiation and survival of a small number of cells that produce milk during lactation.242 These 
secretory epithelial cells are located at the very end of the ductal tree and are postulated to be the 
primary site of the malignant transformation. Using transgenic mice, it was shown that STAT5a loss 
leads to delayed breast cancer development in several breast cancer models.243,244 On the other hand, 
overexpression of STAT5a led to sporadic tumour development in older mice.245 Some studies 
conclude that STAT5b is important for proliferation of breast cancer cells, as its deletion leads to 
apoptosis induction while other groups report a very mild effect of STAT5b overexpression on 
cancer development. 246,247  
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Nuclear localisation and the activity of STAT5 are frequently detected in tumour tissues 
from breast cancer patients. Intriguingly, activated STAT5 correlates with an increased survival and 
generally a good prognosis in breast cancer.245,248 Tumours with activated STAT5 are better 
differentiated and are more responsive to the endocrine treatment.249,250 This points out that at the 
later stages of tumour development STAT5 seems to play an anti-tumourigenic role. One of the 
proposed mechanisms is inhibition of the invasive phenotype by the repression of MMP-2 and 
BCL6 expression.251,252 Clearly, the functions of STAT5 in breast malignant transformation and 
tumour progression are different. However, the mechanism behind the role of STAT5 in the good 
prognosis of breast cancer remains to be fully investigated.  
STAT5 has been shown to be constitutively activated in various tumours of the 
hematopoietic system (e.g., AML, CML, myeloproliferative disorders).253,254 The persistent activity 
is usually driven by genetic aberrations in the upstream kinases, for instance, JAK2V617F 
hyperactivating mutation (in polycythemia vera), BCR-ABL fusion (in CML) or FLT3 kinase 
mutations (in AML).255-257 Consistent with the physiological function of STAT5 to maintain the 
survival of pro-B-cells during lymphopoiesis (for example, through Mcl1 expression), abnormally 
activated STAT5 promotes survival, proliferation, and resistance to apoptosis of the malignant cells 
as well.258,259 Additionally, it enhances the levels of such cancer-related genes as cyclin D1, BCL-
xL, c-myc, Pim1 and represses the pro-apoptotic miRNAs miR15/16.260-262  
Also, STAT5 may play an additional role in tumourigenesis through regulation of the 
tumour milieu. STAT5 regulates FOXP3 that induces differentiation of the Th17 cells providing 
immune tolerance.263 On the other hand, STAT5 is critical for the maintenance and survival of the 
cytotoxic NK cells.264 In conclusion, STAT5 plays a complex role in the immune regulation and 
immune surveillance that complicates the role of STAT5-specific inhibitors in blood cancers. 
 
 
1.4.6 STAT6  
The function of STAT6 has been primarily associated with the activation and proliferation 
of the immune cells. It is activated by IL4 and IL13 which signal through the IL4- and IL13-
receptors, respectively (which share the IL4R𝛼 subunit). The receptor chains heterodimerise upon 
the ligand binding, causing JAK1 and JAK3 to cross-phosphorylate each other and the receptor 
subunits. Eventually, STAT6 is activated by phosphorylation on a single tyrosine residue, similar to 
other STATs. In the nucleus, a functional STAT6 dimer binds to GAS, although with low affinity. 
Instead, STAT6 has a unique binding site which contains a 4-base linker between the palindromes. 
Other STATs are not able to bind to this sequence, thus providing specificity for the IL4/STAT6 
response.265  
An additional characteristic feature of STAT6 as a transcription factor is its dependence on 
the complex formation with other transcription factors. Thus, a STAT6 target gene promoter cannot 
be activated by IL4 in vitro outside the promoter context, although a STAT6-dimer recognises its 
binding site. If C/EBP or NF-𝜅B sites are positioned in close proximity to a STAT6 site, the 
promoter gets fully activated.266 The requirement of other proteins for the STAT6 transcriptional 
activity might  explain the fact that the transactivation domain of STAT6 is drastically different 
from the TAD of other STAT proteins.130,267  
The main transcriptional result of the STAT6 activity is the regulation of the Th2 cells 
activity and immunoglobulin switch. There is a report that shows the overexpression of STAT6 in 
the dedifferentiated liposarcomas and mesenchymal tumours.268 Overexpression of STAT6 in breast 
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cancer cell lines leads to inhibition of cell proliferation.269 The precise role and the mechanisms of 
STAT6 activity outside the immune cells are not clearly defined.270  
 
 
1.5 THE DUAL ROLE OF STAT1 IN CANCER 
 
STAT1 was discovered as a mediator of the IFN signalling. It was the first ever described 
example of the extracellular signal transduction to the nucleus without a direct contact.271 The 
tumour suppressive activity of IFN has been attributed to STAT1 (or to STAT2 by different 
groups).272,273  
STAT1 functions through the well-described transcriptional complexes, ISGF3 and 
STAT1/STAT1 homodimers, both of which require prior phosphorylation. Alternative complexes— 
ISGF3 without IRF9, for example—have also been described,274 but the complete ISGF3 is a much 
more potent transcription factor. However, as it was demonstrated using a STAT1-null cell line 
U3A and its subline reconstituted with a STAT1 mutant that is unable to form dimers, 
unphosphorylated STAT1 also possesses transcriptional activity.275  
Soon after the discovery of STAT1, it became evident that its function is also very context-
and cell-type-dependent. This resulted in contradictory reports describing STAT1 both as a tumour 
suppressor and as an oncogene. However, one should distinguish between the protein levels of total 
STAT1, pSTAT1, and the mRNA expression level of STAT1, as they might not correlate with each 
other. It is not always obvious whether it is localisation or expression of STAT1 that reflects its 
activity in each cancer type. Also, the non-transcriptional functions of STAT1 cannot be excluded 
to play a role in tumourigenesis.276-278 Furthermore, a recent ChIP-seq study that investigated the 
whole-genome binding sites of STAT1 concluded that a GAS-site is not a pre-requisite for STAT1 
binding. GAS - sdjacent sites may provide a more complex regulatory mechanism of STAT1-driven 
transcriptional regulation. 
The tumour-suppressive function of STAT1 is conveyed mainly by regulation of 
transcription of the target genes. It activates the expression of cell cycle regulators (e.g., p21 and 
p27), pro-apoptotic proteins (e.g., BAD, Bax, Bak, caspase 1, 2, and 3),279,280 death receptor and its 
ligands FAS and FASL, DR5, and TRAIL.281,282 STAT1 is also a potent transcriptional repressor as 
it inhibits expression of the genes such as anti-apoptotic Bcl-2 family members283 and pro-
angiogenic factors as VEGF and MMP2.284 Some evidence suggests that  STAT1 can complex with 
p53 thus releasing the repressive complex with MDM2 and facilitating the transcriptional activity of 
p53 and the consequent cell cycle arrest.285 
The tumour promoting role of STAT1 was recognised soon after its discovery and 
continues to be reported in different systems.286-288 In breast cancer, the oncogenic role of STAT1 
was attributed to ISG15.289 In other studies, it was shown that STAT1 can complex with MUC1, 
thus providing its own constitutive activation and expression of target genes including MUC1 and 
MUC4 that are considered the hallmarks of the epithelial transformation.289-291 Some other 
mechanisms of the STAT1-induced cancer survival include the upregulation of anti-apoptotic 
proteins,292 suppression of tumour cells immune recognition by the upregulation of PD-L1291 and, 
possibly, many more to be discovered. In some cases, STAT1 acts as an unphosphorylated dimer, 
pointing out that an overexpressed protein can gain (un)expected functions even in the absence of 
activation. 
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To coclude, a former tumour suppressor STAT1 can have an opposite function when the 
context is changed. It appears that STAT1 is more than just a transducer of the signal from IFNs to 
the nucleus. 
 
1.6 IRDS IN CANCER 
A special case of the pro-tumourigenic effect of STAT1 is the induction of drug resistance. 
In an initial experiment by Khodarev et al. radiosensitive breast cancer xenografts were subjected to 
repetitive cycles of radiation. Eventually, the radio-resistant tumours were selected. When the gene 
expression profiles of the primary tumours and the radio-resistant tumours were compared, a gene 
signature later termed IRDS (interferon-related DNA damage signature) was discovered.76 This 
gene set contained 31 known ISGs. Later it was established that IRDS is upregulated in tumours in 
response to the fractionated treatment with ionising radiation and chemotherapy.293,294 Furthermore, 
these results were reproduced in the clinical samples of therapy-sensitive and therapy-resistant 
tumours of different origin, including breast cancer.295,296 
Further studies by the same group identified STAT1 as the main driver of resistance. 
Overexpression experiments demonstrated that STAT1 conferred the resistance to breast cancer 
cells while stable downregulation of STAT1 by RNAi led to an increase in therapy sensitivity. 
Moreover, the docetaxel-resistant prostate cancer cells selected by a long-term exposure to low 
doses of the drug showed an increase in the expression of STAT1 compared to the parental cells. 
The cells could be re-sensitised to docetaxel when STAT1 was knocked-down.297 Other groups 
obtained similar results in both haematological and solid cancers.298-300 Notably, STAT1 and a 
subset of ISGs were found upregulated both in the primary and in the acquired resistance. 
IFNs type I and II were proposed to be the triggers of STAT1 activity.301 Chronic exposure 
to IFNs leads to constitutively elevated levels of ISGs long after treatment cessation. According to 
the suggested model, cells are selectively pressured for the survival during the early cancer 
development. Since the immune system tries to eliminate or growth-restrain the malignant cells, it 
will lead to the selection of the clone that is the most efficient in withstanding the growth-
suppressive effects of the microenvironment. The resistance to cytotoxic drugs would be a 
secondary effect of this adaptation.302,303 
Regarding the mechanisms underlying therapy resistance, not much is yet known. There is a 
report on the involvement of MUC-proteins into STAT1-mediated therapy resistance as described 
above,290 however, the exact mechanisms and the contribution of the individual downstream ISGs 
into cell survival are not elucidated. Upon chronic exposure of the cells to the low-dose IFNs 
unphosphorylated STAT1 will accumulate. U-STATs (including U-STAT1) are transcriptionally 
active, and their target genes are not fully redundant with the classical IFN-induced genes but 
closely resemble IRDS.304 Clarifying this issue would contribute to our understanding of the 
resistance mechanism and would greatly aid in the identification of novel biomarkers of therapy 
response. 
A gene signature similar to IRDS was also associated with the reduced risk of bone 
metastases in breast cancer.305 Parker et al. identified an IRF7-regulated gene signature that was 
absent in the bone metastases but present in the primary tumours. Moreover, they provided 
experimental evidence that IFN treatment and, hence, upregulation of ISGs leads to the reversion of 
the metastatic phenotype and prolongs overall survival. However, the IRF7-signature correlated 
inversely only with the development of the bone metastasis and did not correlate with the lung 
metastasis. In their recent work, the same group showed that the endogenous IFN-signalling is 
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necessary for the activity of the NK-cells.306 This result might indicate that the IRDS 
downregulation (or the downregulation of a similar signature) can be beneficial for tumour cells to 
disseminate and establish themselves in a new site where an immunosuppressive environment has 
not yet been created.  
The discrepancy between different studies on the role of ISGs in the cancer progression and 
therapy response remains yet to be explained. The tissue specificity may play a decisive role, 
although both studies described above (by Khodarev et al. and by Parker et al.) were done on breast 
cancer models. Additional investigations are necessary to determine whether these different reports 
contradict each other, or they are just two sides of the same coin.  
 
1.7 HSP90 INHIBITORS AS AN ANTI-CANCER TREATMENT 
 
Heat shock proteins are a special group of proteins involved in cancer development. There 
have been at least five main families of heat shock proteins described: Hsp100, Hsp90, Hsp70, 
Hsp60, and Hsp27. They are either constitutively expressed in distinct cell compartments or are 
induced by specific stimuli. Tumour cells are particularly dependent on Hsp90, much more than 
normal cells.307 
Heat shock protein 90 (Hsp90) is a ubiquitously expressed molecular chaperone that 
maintains cell protein homoeostasis under normal and, especially, stress conditions. There are 
several proteins in the Hsp90 family: cytoplasmic Hsp90𝛼 (constitutive) and Hsp90𝛽	(inducible), 
mitochondrial TRAP, and endoplasmic Grp94. The cytoplasmic forms are particularly important for 
cell survival. In normal cells, Hsp90 is involved in folding, modifications, and functionality of the 
key proteins necessary for cell survival and proliferation.308 Also, Hsp90 recognises altered and 
terminally damaged proteins and mediates their incorporation into lysosomes and autophagic 
degradation309 or degradation by a ubiquitin-proteasome system. It can also trigger an unfolded 
protein response upon the accumulation of damaged or non-folded proteins leading to the 
translation inhibition and the enhancement of heat shock proteins activity. 
There are three major domains in Hsp90 proteins: an N-terminal domain with ATPase 
activity, a C-terminal domain with an interaction site between Hsp90 proteins, and a middle domain 
where a client protein binds. Under basal conditions, Hsp90 is kept in an open conformation (ADP-
bound) and interacts with another Hsp90 protein through the C-terminal parts. The current model of 
the Hsp90 function implies a two-step activation process. First, Hsp70 together with its co-
chaperones bind a client protein and bring it to Hsp90. In an open confirmation, Hsp90 interacts 
with a co-chaperone HOP, which binds the complex of the Hsp70/client protein and presents it to 
Hsp90. Binding of the client protein to the middle domain of the Hsp90 complex triggers the ADP 
to ATP exchange followed by the conformational switch from the open to the shut form where 
Hsp90 monomers interact through the N-terminal domains, middle domains through the client 
protein, and the C-terminal domain through ATP. At this stage, the dissociation of the Hsp70 
complex takes place. Hsp90 co-chaperones bind to the shut Hsp90 complex and provide the 
ultimately functional protein state.310  
Since many of the Hsp90 clients are critical for the tumour cell survival, they need to be 
maintained functional under endogenous and exogenous stress caused by hypoxia, acidosis, 
nutrients deprivation, chemotherapeutics, etc. Therefore, cancer cells actively utilise Hsp90 in the 
repair of damaged proteins and, in this way, Hsp90 contributes to sustaining survival and 
proliferation. Hence, overexpression of Hsp90 is often detected in cancer and is correlated with 
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poor outcome.311-313 The clients of Hsp90 include growth factor receptors (e.g., EGFR), tyrosine 
kinases (e.g., MEK, AKT), transcription factors (e.g., p53, androgen receptors) and structural 
proteins (e.g., tubulins), many of which are upregulated in cancer. Hsp90 interacts with proteins in 
their mature form (compared to, for example, Hsp70 clients). It maintains the optimal conformation 
of the client proteins ready for the prompt response to a stimulus (e.g., it keeps phosphorylation 
sites and points of interactions with other proteins exposed, etc.). Despite a large number of clients, 
it has not been possible yet to identify any common motifs which Hsp90 could recognise.314 A 
recent study demonstrates that there is a certain principle of recognition and that the number of 
clients is definite.315 It is clear, however, that there is a selectivity comparing to Hsp70s which can 
bind virtually any protein. 
Since Hsp90 clients include many known oncogenes or other proteins involved in tumour 
survival and progression, one could speculate that Hsp90 is involved in maintaining all main 
hallmarks of cancer. Experience with the proteasome inhibitor bortezomib has shown that cancer 
cells do not tolerate the accumulation of misfolded proteins and undergo apoptosis upon the 
treatment with this drug. Targeting Hsp90 also leads to the accumulation of unfolded proteins; 
therefore, Hsp90 inhibition was proposed to be an efficient strategy either by itself or in 
combination with other drugs.  
Indeed, numerous studies report the induction of the cell death upon treatment with Hsp90 
inhibitors and beneficial effects of combining them with the conventional treatments. To date, 
several generations of Hsp90 inhibitors have been developed. 
The first class of the inhibitors included geldanamycin and radicicol. Although structurally 
unrelated to each other, these compounds functioned through outcompeting ATP binding to the N-
terminal domain of Hsp90 proteins. The drugs also increased the recruitment of ubiquitin ligases to 
the Hsp90 complex, leading to the degradation of Hsp90 client proteins. The use of these inhibitors 
in the clinic was not pursued due to their intolerable toxicity.  
The second generation of the Hsp90 inhibitors included two derivatives of geldanamycin, 
17-AAG and 17-DMAG. 17-AAG was demonstrated to have ≈100-fold increased affinity to Hsp90 
in cancer cells than in normal cells, thus pointing out for the first time that Hsp90 inhibitors are 
more specific to tumour cells.316 Several clinical trials have been conducted using this drug either as 
a single agent or in a combination with docetaxel, bortezomib, trastuzumab, and rituximab.317 Since 
HER2 is a proven target of Hsp90, many trials focused specifically on breast cancer. Good clinical 
response was observed in the metastatic HER2+ cancers in the combination with trastuzumab for 
the tumours that progressed on the monotherapy with trastuzumab.318 Introducing 17-AAG into the 
clinic was hampered, though, by poor pharmacokinetics. As a derivative of 17-AAG with improved 
solubility, 17-DMAG was also tested in clinical trials and showed promising activity,319 but its 
toxicity led to the termination of all trials as well. One of the proposed toxicity mechanism is 
gluthathione depletion.320 
The third generation of the Hsp90 inhibitors includes synthetic compounds based on the 
structures of 17-AAG and radicicol. One of the most promising drugs tested in clinical trials is 
STA-9090 (ganetespib).321-324 
Currently, there are 15 active clinical trials with Hsp90 inhibitors and about 50 trials are 
completed. The major problem, apart from the toxicity, is that there are very few proposed 
biomarkers for the response to Hsp90 inhibitors. Usually, the levels/activity of the likely important 
client protein is assessed. Also, peripheral levels of Hsp70 are controlled, its increased expression 
being a sign of the response to Hsp90 inhibition. However, these tests only show the  
pharmacodynamic response ( i.e., that the drug does affect Hsp90) and do not predict the clinical 
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response to treatment.325 Another problem is that in cancer, Hsp70 can partially substitute the Hsp90 
function, rendering cells resistant to the treatment. Double inhibitors of Hsp90 and Hsp70 have been 
reported to be efficient and are under currently in the preclinical development.326,327 
Also, it became evident that not all Hsp90 clients are equally sensitive to the chaperone 
inhibition. HER2 in breast cancer and ALK in lung cancer, for example, are very sensitive, while 
AR, although also an Hsp90 client, does not seem to be affected by Hsp90 inhibitors.328,329 
Therefore, a careful selection of the responsive cancers should be carried out; currently, there is no 
available marker predictive of the response. 
Multiple myeloma (MM) was proposed to be a cancer type that is highly dependent on the 
protein handling pathways. This partially explains the success of bortezomib in the treatment of this 
malignancy and suggests that the use of Hsp90 inhibitors would be beneficial as well. Also, it 
appears that several pro-survival pathways in MM cells are the clients of Hsp90 (e.g., IL6/STAT3, 
PI3K/AKT, MAPK). Indeed, pre-clinical studies showed that MM cell lines are relatively sensitive 
to the Hsp90 inhibitors, but there is a fraction of the cell lines and patient-derived cells which are 
resistant.330,331 Several clinical trials have been conducted evaluating the safety and efficiency of the 
Hsp90 inhibitors in this type of cancer, either alone or in combination with bortezomib.332,333 These 
studies also confirmed that there is only a subgroup of patients that shows a clinical response to the 
Hsp90 inhibitors. 
In conclusion, targeting Hsp90 is a feasible strategy in anti-cancer treatment. To maximise 
the benefit of theHsp90 inhibition, treatment response biomarkers and rational combinational 
protocols should be developed. 
 
1.8 STRATEGIES FOR TARGETING STAT3 IN TUMOURS 
 
The first successful attempt to intervene with the STAT3 activity in cancer took place more 
than 15 years ago by H. Yu and R. Jove.334 Using a dominant-negative mutant of STAT3 in a 
xenograft melanoma model, they demonstrated for the first time that inhibiting STAT3 activity 
prevents tumour growth. From these and later experiments using RNAi, dominant negative mutants, 
and conditional knock-outs, it was concluded that STAT3 inhibitors would be beneficial for treating 
cancer.335  
The first proof-of-principle inhibitor was developed by Turkson et al. in 2001. It was a 
peptide binding the SH2 domain, thus preventing the phosphorylation and dimer formation.336 Since 
then, inhibitors intended for the therapeutic use are constantly being developed. They all provide the 
evidence that it is possible to target STAT3 by non-peptide inhibitors, but their incorporation into 
the oncological treatment has not been successful yet. 
Below, I outline the main groups of inhibitors developed so far and some of the approved 
drugs which indirectly influence STAT3 activity. 
 
Peptidomimetics 
The Tyr-SH2-domain binding peptide was effective in high concentrations in vitro. Non-
peptide drugs that mimic its effect (ISS-610 and S3I-2001) were developed later and were shown to 
be effective in different malignant cell lines and xenograft models.337,338 Phosphopeptides derived 
from LIF, gp130, EGFR and IL10 were also found to bind the SH2 domain of STAT3.339 These 
studies resulted in the development of a peptidomimetic inhibitor of STAT3 with an IC50=150 
nM.340 The peptide from the SH2 domain of STAT3 was also modified and shown to bind STAT3, 
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albeit weakly, and inhibit cancer cell growth in vivo.341,342 More attempts to improve 
phosphopeptides resulted in the development of the relatively potent SH2 domain binders in vitro, 
which failed, however, to inhibit important STAT3-regulated genes.343 Currently, it is believed that 
the problems with stability and permeability of phosphopeptides and mimetics outweigh their 
efficiency in vivo. 
 
Decoy oligonucleotides 
An elegant approach for the STAT3 activity inhibition is sponging the activated dimers by 
short decoy oligodeoxynucleotides (ODN). Initially, STAT3 ODN decoys were designed using the 
nucleotide sequence of the STAT3 binding site from the FOS promoter that was slightly modified to 
increase the efficiency. When injected intratumourously, ODN decoy promoted tumour regression 
in glioblastoma344 and was able to resensitise bladder cancer and head and neck squamous 
carcinoma cells to Cetuximab and Erlotinib.345 Moreover, initial safety trials showed a lack of 
toxicity from decoy ODN and evident inhibition of the STAT3-regulated genes in the tumours. 
There are studies currently under way to evaluate the possibility of STAT3 ODN modification to 
provide stability sufficient for systemic administration. 346-348 
 
Natural product derivatives 
Traditional medicines and plant extracts are a rich source of biologically active substances. 
During the most recent decade, attempts have been undertaken to study their effects in experimental 
systems with the aim of developing novel drugs. Although tumour-suppressive and pro-apoptotic 
effects of natural compounds are often observed, it is usually problematic to identify the 
mechanisms of their action and primary targets of such treatments. Inhibition of the STAT3 
phosphorylation correlated with the induction of apoptosis has been one of the effects pointing at 
the potential of some of these natural products.  
Curcumin, a product from Curcuma longa, showed effectiveness in lung and gastric cancer 
xenograft models.349,350 The inhibition of IL6 secretion and the abrogation of STAT3 and NF-κB 
activities have been attributed to the activity of this compound. The promising results prompted the 
development of more potent and bioavailable curcumin derivatives (FLLL32, HO-3867, LLL12, 
etc.) with reported activity in different cancer types.351-354 As far as the mechanism is concerned, 
there is a report that some of the derivatives can prevent STAT3 dimerisation through binding to the 
SH2 domains.353,354 For the majority of curcumin-like derivatives, the mechanism and primary 
targets are not clear. Due to their potency, curcumin-like inhibitors are now being tested in clinical 
trials for different cancer types and the inflammatory diseases. Interestingly, curcumin has been 
named as one of PAIN compounds ‘worst offenders’ and it is claimed to be a covalent modifier and 
membrane disruptor.355 It is likely that it blocks multiple signalling pathways coming from 
membrane receptors and, therefore, can be a potent but highly unspecific STAT3 inhibitor. 
Some of the other clinically relevant natural product derivatives with activity against 
STAT3 are 3,3’-diindolylmethane,356 oleanolic acid357 and resveratrol.358 The derivatives of these 
substances are currently undergoing evaluation in clinical trials (most at phase I-II) for cancer, 
multiple sclerosis, RA, and even Alzheimer’s disease. Pre-clinical experiments demonstrated that 
treatment with these compounds leads to the downregulation of important STAT3 target genes. The 
mechanisms of action are not well understood, and the inhibition of STAT3 activity might be a 
secondary effect. 
Apart from those named above, there are a plethora of other natural product derivatives 
with anti-cancer activity that affect STAT3. As was mentioned earlier, STAT3 gets inputs from 
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multiple signalling molecules. Therefore, it is not surprising that the tumour - suppressive effect of 
many natural products is associated with the inhibition of STAT3 phosphorylation.  
 
Tyrosine kinase inhibitors 
Receptors with tyrosine kinase activity are frequently mutated or amplified in cancer. This 
leads to the self-sufficiency of cancer cells, makes them independent of the external stimuli and 
provides constitutive pro-survival signalling.9 Many relatively specific tyrosine kinase inhibitors 
were developed during the last 15 years, both antibodies and small molecules. Although good 
clinical response is observed upon the initial treatment, resistance develops in almost 100% of the 
cases. The mechanisms of resistance to targeted therapies are the subject of extensive study. In 
some cases, STAT3 activation upon drug treatment can be one of the mechanisms that provide a 
survival advantage for cancer cells, especially in tumours that originally did not harbour a 
constitutively activated STAT3. 
On the other hand, tumours with STAT3-addiction can regress upon treatment with tyrosine 
kinase inhibitors. Indeed, several drugs have a documented inhibitory effect on STAT3. For 
example, Imatinib, Erlotinib, and Sorafenib were designed to target specific tyrosine kinases (BCR-
ABL, EGFR, and Ras respectively), and they all inhibit STAT3 as well.359-361 Thus, one of the 
mechanisms of their action might be the STAT3 inhibition.362-364  
A special case of tyrosine kinase inhibitors affecting STAT3 phosphorylation is JAK 
inhibitors. JAK-activating mutations have been seen in several cancer types; therefore, there is a 
good basis for the use of JAK inhibitors (selective or pan) in oncological treatment. However, it was 
in the autoimmune diseases (e.g., RA) that JAK-inhibitors were first used. Currently, there are 
several FDA-approved JAK inhibitors in use (e.g., Tofacitinib, Ruxolitinib) and in trials for cancers, 
and many more are under development and in early stages of trials.365-370  
 
Platinum-based and microtubule-targeting drugs 
Traditional chemotherapy remains the main treatment for cancer. Therefore, a lot of studies 
have focused on the mechanism of action and resistance to these drugs. Although multiple pathways 
are affected by chemotherapeutics, STAT3 inhibition was proposed as one of the contributing 
factors to the cell death in response to the treatment.371 
At the same time, resistance to these chemotherapeutics has been attributed to STAT3 
activation in some cancers.372-374 For example, ovarian carcinoma cells gradually upregulate STAT3 
in response to cisplatin treatment and eventually become resistant to the treatment. However, they 
can be treated by oxaliplatin, other platinum-based compound, that downregulates STAT3 
phosphorylation on tyrosine, but induces phosphorylation on serine and the increases the expression 
of STAT3β.375  
 
TLR-conjugated siSTAT3. 
Tumour microenvironment has been shown to be important for tumour growth support. 
Abnormal activity of STAT3 has been detected not only in cancer cells but also in the immune cells 
of the tumour niche. This results in the reciprocal activation circle between cancer cells and residing 
immune cells, providing a constant flow of growth factors and cytokines. On the other hand, 
myeloid cells with constitutively expressed STAT3 secrete immunosuppressive cytokines, thus 
preventing the immune-mediated elimination of the tumour. In an attempt to exploit this 
phenomenon, Yu et al. and Kortylewski et al. have developed a system of intracellular siSTAT3 
delivery where they conjugated a TLR9 derivative with siSTAT3.376 Through TLR-part, this 
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complex is recognised and engulfed by the residing Th1 lymphocytes, which results in the ablation 
of their activity. Under these conditions, adoptively transferred T-lymphocytes can efficiently target 
tumour cells.348 Also, TLR9 signalling was found to be an important contributing factor for tumour 
development and recurrence, also through the regulation of IL6 production. Therefore, a TLR9-
siSTAT3 conjugate might potentially kill two birds with one stone.377 The modified system with 
CpG-conjugated STAT3 decoy oligonucleotides was also effective in targeting STAT3 in acute 
lymphoblastic leukaemia.378  
 
Direct STAT-specific small molecule inhibitors 
The last five to 10 years have been prolific regarding the development of STAT3 inhibitors. 
A multitude of small molecules with different potency and specificity are reported to inhibit STAT3 
activity in different experimental systems. I would like to briefly outline the milestones of the 
STAT3 small molecule inhibitors development (more from the  the point of view of a cancer 
biologist than a medicinal chemist). 
 
STA-21 was one of the first inhibitors with STAT3 inhibitory activity that was identified by 
the virtual screening of the National Cancer Institute (NCI) library collection combined with the 
drug libraries from Sigma-Aldrich and Ryan.379 The 3D structures of the compounds were generated 
and docked against the SH2 domain of STAT3. One hundred compounds from the NCI library were 
then validated in breast cancer cell lines with constitutively active STAT3. A STAT-responsive 
luciferase reporter was stably transfected, and the clones with the highest luciferase expression were 
subjected to the 48h treatment with 20µM of the compounds. STA-21 was selected after this 
screening and was shown to inhibit the STAT3 DNA-binding activity in the cells. A derivative of 
STA-21 with improved pharmacological characteristics showed the activity against glioblastoma in 
a mouse model.380 LLL compound series based on the functional centres of STA-21 was patented in 
an attempt to optimise SAR of STA-21. 
 
STATTIC was identified by screening the collection of ≈18,000 compounds in a 
fluorescence-based polarisation assay.381 Due to its small size and, possibly, promiscuity382 it has 
not become a drug, but an important tool for studying STAT3 activity. Also, the paper reporting the 
discovery of STATTIC set a standard and the minimal requirements for the validation procedure of 
STAT3 inhibitors: in vitro binding assay, cellular essay (e.g. a reporter), EMSA for DNA binding, 
immunofluorescent staining for the nuclear translocation, Western blotting for the induced 
phosphorylation of STAT3 and STAT1, effect on other proteins in the pathway (e.g., JAKs, JNK 
for IL6-induced STAT3) and the differential effect in the STAT3-dependent and -independent cell 
lines.  
Turkson et al.383 identified S3I-201. Virtual screening of diverse compounds identified a 
molecular probe structurally different from previously described STA-21 and STATTIC. The 
potency of this compound was rather low (up to 100 µM for 24h in the reporter assay in a SRC-
transformed cell line). However, this report was the first to show not only the selectivity of the 
inhibitor towards the cells harbouring activated STAT3, but also inhibition of a STAT3-dependent 
gene transcription (Cyclin D1, Bcl-xL, and survivin). Also, S3I-201 was tested in vivo and showed 
a tumour suppressive effect in a breast cancer xenograft model. 
 
BP-1-102 is a derivative of S3I-201.384 It was designed using a computer-aided lead 
optimisation program. It is much more potent than S3I-201, but, most importantly, it is the first 
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orally bioavailable STAT3 inhibitor. Recently, though, a concern was raised regarding its 
specificity and suitability as a drug.385 
 
OPB-31121 is the only small molecule inhibitor of STAT3 that has reached the clinical 
trials stage and demonstrated some clinical efficacy.386 It is described in the initial report as a 
‘STAT inhibitor’ and is shown to inhibit both STAT3 and STAT5. The structure was recently 
described, and it seems to target the SH2 domain of STAT3, however, at a non-conventional site.387 
The modified version of the compound (OPB-51162) is currently being tested in clinical trials, also 
with variable response.388 It is clear now that not all tumours with activated STAT3 respond equally 
well,389-391 and it remains to be seen whether this compound will make it into a routine anti-cancer 
treatment. 
 
1.9 A DISEASE MODEL USED IN THE THESIS 
 
1.9.1 Multiple myeloma 
 
Clinical view 
Multiple myeloma is a malignancy characterised by the clonal expansion of plasma cells in 
the bone marrow. It accounts for about 1% of all diagnosed cancers and 13% of haematological 
malignancies. The median age at diagnosis is 65-70 years; the incidence is higher in men; African-
American background is an additional risk factor. The disease-associated deaths are tightly 
connected to the age: In the group diagnosed before 65 years, the five-year overall survival is ≈50% 
while the mortality rates rise steadily and sharply with each additional five years. 
The progression of myeloma, as with any other cancer, is a multi-step process of 
accumulation of genetic and epigenetic mutations causing the survival advantage of a particular 
clone of plasma cells. A non-malignant, asymptomatic condition called monoclonal gammopathy of 
undetermined significance (MGUS) precedes the development of multiple myeloma in most of the 
patients. MGUS progresses to myeloma at the rate of about 1% per year.392 The next step in MM 
progression is smouldering (indolent) myeloma (SMM), a more aggressive, but still a non-
malignant and asymptomatic condition with a 10% rate of progression to clinical MM per year.393 
The current staging system of MM is based on serum concentrations of β-macroglobulin 
and albumin (the higher the concentration, the higher the is a disease stage and the worse prognosis 
patient has). Also, cytogenetic FISH assessment of infiltrating bone marrow cells can be used: 
t(4;14), t(4;16) and 17p deletion are associated with poor prognosis.  
The induction therapy usually includes bortezomib and dexamethasone, with or without the 
addition of the third drug, such as thalidomide, doxorubicin, or cyclophosphamide.394 In the event of 
a good response, the same therapy is prescribed for three to four cycles before the cell 
transplantation.395,396 The patients who do not qualify for the stem cell transplantation (the elderly or 
the cachectic) receive a treatment with melphalan and prednisolone, often with thalidomide, 
bortezomib, or cyclophosphamide.397,398 
Despite the grading system and some prognostic value of cytogenetic data, the patients are 
currently not stratified based on these criteria. Therefore, even patients with a relatively good 
prognosis receive the full treatment due to a general high mortality risk in this disease. 
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Biological view 
MM arises from the transformation of the plasma cells that are terminally differentiated B-
cells arrested in the G0/G1 cell cycle phase. The primary event leading to MM development is 
believed to be the acquisition of the proliferation ability through activation of D-type cyclins by 
plasma cells. One proposed mechanism for this event is the chromosomal translocation 
t(11;14)(q13;q32) that leads to the expression of Cyclin D1 under the control of the heavy chain 
enhancer. Alternative mechanisms include deregulations in histone methyltransferase MMSET 
through the t(4;14)(p16;q32) translocation that leads to the increase of H3K36me2 across the 
genome, that in turn de-represses the transcription of a Cyclin D gene. Upon other chromosomal re-
arrangements, Maf transcription factors, which also control the expression of Cyclin D2, can be 
activated. Apart from that, hyperdiploidy (especially trisomy 11) can also lead to the increased 
expression of cyclins. 
Since the number of plasma cells in the bone marrow increases during the progression from 
MGUS to SMM and MM, the cells are believed to get additional proliferation advantages. This may 
happen through the upregulation of Ras and Myc.399,400 Additionally, chromosome 13 might be 
deleted leading to insufficiency in the production of a tumour suppressive Rb-protein.401 
The terminal stage of MM is characterised by the stroma-independent growth that leads to 
extramedullar diseases and plasma cell leukaemia. 
 
Pro-survival pathways in multiple myeloma 
Although it has been shown that plasma cells can survive and even slowly proliferate 
outside the bone marrow,402 stroma of the bone marrow (BMS) is essential for their survival and 
progression. Since the bone marrow is normally a place of haematopoiesis, stroma cells produce a 
variety of cytokines and growth factors meant to support rapid proliferation and survival of the 
blood cells (e.g., IL6, IL10, IL-1β, VEGF, bFGF, etc.). Tumour cells hijack the bone marrow 
microenvironment to maximise their own growth, proliferation, and survival. To avoid the immune 
system-mediated control, proliferating tumour cells suppress the local immune system and cause 
irreversible lytic destruction of the bone marrow matrix. 
Accumulated genetic abnormalities lead to the abnormal expression of the cell surface 
adhesion molecules, thus retaining the cells within the bone marrow microenvironment. Interactions 
of the plasma cells with the stromal cells lead to the upregulation and alteration of cytokine and 
growth factor secretion reciprocally by the stromal cells and by the plasma cells. Concurrently, an 
interaction with the proteins of the extracellular matrix (e.g., collagen, fibronectin, etc.) together 
with a changed cytokine repertoire lead to apoptosis inhibition and cell cycle progression.403  
IL6 is considered to be the main growth factor for myeloma cells.404,405 At earlier stages of 
myeloma development, it is produced by stromal cells; however, continuous exposure to IL6 leads 
to the autocrine secretion of this cytokine by MM cells. IL6 activates at least three signalling 
pathways: JAK/STAT3, RAS/MAPK, and PI3K/Akt that were shown to provide the proliferation 
and survival advantage of the malignant plasma cells. 
IGF-1 is also an important factor that stimulates the proliferation of both IL6-dependent and 
IL6-independent cell lines through the regulation of PI3K pathway, and also of the MAPK 
cascade.406,407  
VEGF is yet another essential growth factor for MM cells, especially for the refractory 
MM. It has been shown that VEGF increases the expression of anti-apoptotic proteins such as Mcl-
1 and survivin, and also induces cell proliferation by activating a Ras/MEK/Erk pathway. Pre-
clinical studies show that anti-VEGF antibodies and small molecule inhibitors of VEGF slow down 
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proliferation and induce cell death in MM cell lines.408 Also, there is experimental evidence that a 
combination of bortezomib with an anti-VEGF drug has a synergistic effect.409 
Activated Wnt signalling has also been detected in MM. It leads to nuclear accumulation of 
β-catenin and promotes the proliferation of plasma cells. Also, Wnt signalling increases the 
expression of the Wnt inhibitor Dkk1 required for the survival of osteoblasts and prevention of bone 
resorption under normal conditions. 
To summarise, MM remains an incurable disease where it has been difficult to achieve long 
remissions. It also appears that ‘multiple myeloma’ is a term that encompasses several distinct 
diseases with the common feature of clonal plasma cells expansion in the bone marrow and 
antibody production. Several signalling pathways collaborate in plasma cells to promote their 
survival. Moreover, populations of myeloma cells with a different phenotype can be identified in a 
single patient. The use of proteasome inhibitors revolutionised the treatment; however, acquired 
resistance is a serious problem. Taken together, the drug combinations for the treatment of multiple 
myeloma should be tailored for each patient. Therefore, it is paramount to investigate different 
cellular subtypes and their signalling pathways. 
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2 THE AIMS OF THE THESIS 
 
The overall aim of this thesis was to investigate the mechanisms leading to therapy resistance in 
human cancers and to identify the markers for the treatment response in different systems. I 
attempted to contribute to the understanding of factors leading to treatment success or failure, as 
this knowledge might lead to the identification of novel drug targets and, eventually, the 
development of new therapeutics. 
 
More specifically, we aimed: 
 
1. to investigate the relative contribution of different signalling pathways leading to apoptosis in 
multiple myeloma cells upon their treatment with IFNα (Paper I); 
 
2. to explore the connection between the expression of IFN-stimulated genes and therapy 
resistance in colon carcinoma (Paper II); 
 
3. to study the involvement of a JAK/STAT3 pathway into apoptosis induction by Hsp90 
inhibitors in multiple myeloma (Paper III); 
 
4. to develop novel compounds targeting an IL6/STAT3 signalling pathway and to investigate 
their mechanisms of action (Paper IV). 
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3 RESULTS AND DISCUSSION 
 
3.1 PAPER I 
‘Activation of STAT1 is required for interferon-mediated cell death.’ 
 
3.1.1 Background and Rationale 
 
IFN is a cytokine produced by cells to trigger the transcription of genes helping in the 
clearance of the viral infections. Recombinant IFN has been used in the treatment of severe viral 
infections (e.g., Hepatitis B), but also in the oncological practice as a therapy for some cancers (e.g., 
malignant melanoma, multiple myeloma, renal cell carcinoma). Although the anti-viral function of 
Type I IFN is studied rather thoroughly, the mechanisms of its pro-apoptotic activity are not clearly 
understood.410 This is one of the limiting factors of the clinical IFNs usage, probably leading to the 
underuse of this pluripotent tool in cancer management. 
 IFN binding to its receptor triggers the signalling through several pathways (e.g., 
JAK/STAT, PI3K/Akt, mTOR, etc. also illustrated in figure 3).61 Our group has previously shown 
that although JAK/STAT is a major pathway induced by IFNα, pharmacological inhibition of PI3K 
or mTOR leads to a partial protection of the U266 multiple myeloma and the Rhek-1 keratinocyte 
cells from the IFN-induced cell death.411 Therefore, we set out to investigate if JAK/STAT 
signalling also plays a role in the IFN-mediated apoptosis of MM cells. 
 
 
3.1.2 Main findings 
 
 The protection of the myeloma cells from the IFN-induced cell death by PI3K or 
mTOR inhibitors was partial. It points out that an additional pathway(s) is involved in the IFN-
mediated apoptosis. We came across the observation that deguelin, a natural compound of the 
rotenoid family, inhibited the IFN-induced phosphorylation of STAT1 in the U266 cell line. 
Inhibition of the STAT1 phosphorylation by deguelin correlated with protection from the IFN-
induced apoptosis, as demonstrated by the reduction of AnnexinV/PI double-positive cells. The 
protective effect of deguelin was also partial, similar to the effects of PI3K and mTOR inhibitors. 
When deguelin was combined with either inhibitor, the cell death induced by IFN was completely 
blocked.  Thus, our experiments have suggested that several pathways need to be involved for the 
full apoptotic effect of IFN. Also, it appears that the phosphorylation of STAT1 is essential for this 
effect of IFN. 
 To further investigate the role of the phosphorylated STAT1 in the apoptosis 
induction, we transfected the mutant forms of STAT1 (STAT1-Y701A and K410/413A) into the 
IFN-sensitive keratinocyte cell line Rhek-1. The STAT1-Y701A mutant is not phosphorylated on a 
crucial Tyr701 residue and the STAT1-K410/413A mutant is not able to move to the nucleus. Upon 
treatment with IFNα, apoptosis was induced in the mock-transfected cells, as shown by FLICA 
staining for active caspases. However, in the cells transfected with either of the two mutants 
apoptosis induction was impaired. This data provides additional evidence that the STAT1 
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phosphorylation and transportation to the nucleus (hence, most probably, the transcriptional 
activity) are necessary for the full pro-apoptotic effect of IFNα. 
Since both chemical and genetic inhibition of the STAT1 phosphorylation protected 
from the IFN-induced cell death, we can conclude that the JAK/STAT pathway activity contributes 
to the induction of the cell death by IFNα. Also, a cooperation between the JAK/STAT pathway 
with other pathways is required for the maximal pro-apoptotic effect of IFN. This data indicates that 
in order to reach the clinical benefit by the IFNα treatment, the functionality of these pathways 
should be preserved.  
 
 
  
 
 
3.2 PAPER II 
‘Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic 
drugs.’ 
3.2.1 Background and Rationale 
 
Since the discovery of Gleevec, many drugs selectively affecting cancer cells have been 
approved. Being designed as “targeted” therapeutics and aimed at specific patient groups, they 
revolutionized the treatment of some types of cancer. However, acquired resistance to therapy is 
inevitably developed, thus preventing cancer cure.412,413  Similarly, chemo- and radiotherapies, 
Figure 3. Schematic illustration of the IFN𝛂-induced pro-apoptotic pathways in a U266 cell line 
used in Paper I. Chemical inhibitors relevant for this study are shown in red rectangles. 
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although effective during the initial treatment, lose their efficiency with each tumour 
recurrence.414,415 Besides, there is a phenomenon of the intrinsic resistance in aggressive cancer 
types that are able to withstand any treatment.416,417 Therefore, further understanding of the 
mechanisms is needed to shed light on the molecular events steering cancer cell survival under the 
treatment. 
Multicellular spheroids (MCS) were entailed as a model in cancer drug development since 
they resemble in vivo tumours in  higher degree than conventional 2D culture.418,419 The monolayers 
(2D) provide all the cells with the uniform access to the abundant nutrients and drug(s), and it 
eliminates heterogeneity and a metabolic stress that are involved in the development of treatment 
resistance.420,421 
We hypothesized that since MCS are more resistant to drugs than 2D cultures,417 this might 
be reflected in their gene expression profile. Therefore, we set out to investigate which genes 
determine drug resistance of the MCS.  
 
3.2.2 Main findings 
 
We performed the microarray comparing the gene signatures of the HCT116 cells (colon 
adenocarcinoma) grown as a monolayer to the same cell line grown as MCS. The upregulated genes 
can be grouped into several gene signatures, such as  those reflecting the metabolic changes caused 
by the compromised environment in the 3D culture (e.g., solute carriers SLC2A3, SLC9A7, stress-
regulated members of MAPK-signalling cascade) or the genes described to be involved into non-
specific multidrug resistance (e.g., ABC1 transporters).422 However, the most prominently 
upregulated genes were so called interferon-stimulated genes  (ISG) that included the members of 
the ISGF3 transcriptional complex. 
We investigated whether this gene signature is restricted to the MCSs of the HCT116 cell 
line. We cultured cell lines of different origin (ovarian, breast, colon carcinomas, transformed 
fibroblasts) in 3D and in 2D and measured the expression levels of the ISGF3 complex members 
(STAT1, STAT2, IRF9) and three ISGs upregulated in the array (IFITM1, IFI27 and OAS1). We 
concluded that the increase in the expression of these genes is rather a general phenomenon. The 
differences in the amplitude of ISGs regulation are cell line specific and, probably, depend, among 
others factors, on the morphology of the spheroids. 
When we used monolayer cultures of HCT116 cells to investigate possible stimuli leading 
to the upregulation of ISGs, we observed that culturing cells over prolonged time leads to a gradual 
accumulation of IRF9, STAT1, STAT2 (on protein as well as on mRNA levels), and to a successive 
increase of IFITM1, IFI27, OAS1 mRNAs. By comparing cells seeded in different amounts (sparse 
to confluent) cultured for 24h, we reasoned that the upregulation of the genes was dependent on the 
density of the cells and, probably, on the cell-to-cell contact, coined by us as “crowding”. 
Since the expression of ISGs is transcriptionally regulated by the ISGF3 complex,423 we 
investigated whether knocking down STAT1, STAT2 and IRF9 in 2D would lead to the 
downregulation of ISGs IFITM1, IFI27, OAS1 upon crowding. The RNAi-mediated STAT1 
targeting did affect neither the expression of ISGs nor IRF9 and STAT2. Knocking down STAT2 
led to the ISGs partial downregulation. On the other hand, reducing the expression of IRF9 most 
prominently affected the genes, including STAT1 and STAT2. Additional experiments with the use 
of a STAT1-negative cell line U3A424 and its parental line 2f-TGH demonstrated that STAT1 was 
not necessary for the ISG density-dependent upregulation, but its presence led to much higher gene 
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expression in this model. Hence, the STAT2/IRF9 complex can effectively induce ISG expression, 
but the presence of STAT1 might promote even higher expression of ISGs in other systems. 
It was described in the literature that a set of genes highly similar to that in the under study 
in this paper (termed “IRDS”) was associated with radio- and chemotherapy resistance in different 
cancer types.295 Moreover, it was shown in mice models that tumours, primarily highly responsive 
to radiotherapy, became successively more resistant with each tumour recurrence.76 The 
development of the resistance was associated with IRDS acquisition. We set to investigate if the 
increased expression of IRF9 changes drug sensitivity in our system. Indeed, moderate 
overexpression of IRF9 alone led to the upregulation of ISGs, and also rendered the cells resistant to 
chemotherapeutics. 
To summarize, we have demonstrated that the 3D culture growth is accompanied by the 
upregulation of ISGs in different cancer types. We have also shown that crowding of cells over time 
and by increasing their density leads to the upregulation of the investigated set of ISGs. The 
regulation is STAT1-independent, but IRF9- and STAT2-dependent in the HCT116 cells, however, 
in other systems STAT1 might be involved to promote even further upregulation of the ISG 
expression. Lastly, the elevated expression of IRF9 alone is sufficient to increase the ISGs 
expression and to promote resistance to the drugs. Establishing the connection between IRF9, the 
ISGs and therapy resistance could lead to the evolution of novel approaches in cancer treatment.    
 
3.3 PAPER III 
‘An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to 
HSP90 inhibitors in multiple myeloma’ 
3.3.1 Background and Rationale 
 
Hsp90 is a molecular chaperone ubiquitously expressed in normal cells and elevated in 
cancer cells of different origin.425 Presumably, the increased expression of the chaperoning complex 
in cancer occurs as a response to the proteotoxic stress caused by the overproduction of proteins 
needed for the survival of a cancer cell.426 The inhibition of Hsp90 leads to cell death in several 
cancer types, and several generations of Hsp90 inhibitors have been developed and tested in clinical 
trials although with modest success so far.427  
Multiple myeloma is a cancer type that particularly relies on the molecular machinery 
maintaining protein homeostasis. This dependency underlies the efficiency of the proteasome 
inhibitor bortezomib in the treatment of this malignancy.428 It was also proposed that the inhibition 
of Hsp90 might provide an additional benefit in the clinical management of MM patients by 
inhibiting critical signalling proteins and by the induction of an unfolded protein response.429 The 
experimental evidence confirmed the effectiveness of the Hsp90 inhibitors in a subset of MM cell 
lines and patient-derived cells.331 Several generations of the Hsp90 inhibitors were tested in clinical 
trials in bortezomib-resistant patients, however, their clinical efficiency was insufficient for further 
implementation. The inclusion criteria into the clinical trials of Hsp90 inhibitors were not based of 
molecular profiling of the malignant cells that could, possibly, explain a  modest overall clinical 
response.430 We hypothesized that the efficiency of the Hsp90 inhibitors might correlate with the 
activity of a signalling pathway particularly dependent on Hsp90 and important for the survival of 
myeloma cells.  
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3.3.2 Main findings 
 
A predominant activity of either IL6/STAT3 or PI3K/Akt pathway was proposed to be 
determined by the presence of an IL6-induced phosphatase CD45 which binds to the IGF-1R and 
dephosphorylates it thereby inhibiting the PI3K pathway activity431,432. We investigated whether the 
response of MM cells to the Hsp90 inhibitors was correlated with the activity of either of these 
pathways. 
First, we characterized a panel of MM cell lines by assessing the basal levels of pSTAT3, 
pAkt, CD45, CD138 and evaluating their sensitivity to the JAK inhibitor Pyr6 and to the PI3K 
inhibitor Ly294002. To summarize, we found that the pSTAT3 positive cell lines expressed CD45 
and responded to the Pyr6 treatment. Conversely, in line with the previous reports, CD45- cells had 
higher levels of pAkt and were sensitive to the inhibition of the PI3K .433 Importantly, all the 
investigated cell lines expressed similar  levels of the Hsp90 protein. 
After that we studied the sensitivity of all the cell lines to the Hsp90 inhibitor 17DMAG. 
We could conclude that the pSTAT3+CD45+ cell lines were much more sensitive to the treatment 
than the pSTAT3-CD45- cell lines. In addition, basal pSTAT3 levels of the sensitive cell lines were 
inhibited upon the treatment with 17DMAG. 
When we cultured the pSTAT3-CD45- cell line LP1 in the presence of IL6 (as described 
in431), we were able to force the phosphorylation of STAT3 and the expression of CD45 in a small 
fraction of the cells. This treatment sensitised the cells to 17DMAG, mostly at the expense of the 
pSTAT3+CD45+ cell population, thus providing evidence that the JAK/STAT3 pathway is 
vulnerable to the Hsp90 inhibition. 
Further, we investigated the presence of distinct cell populations in the MM patient 
samples. Although each sample was a mixture of different subpopulations, it was possible to divide 
the limited number of patient samples we had at our disposal into CD45high - and CD45low- 
expressors. In line with our observations of the cell lines used in this study, CD45high cells had a 
high number of pSTAT3+ cells and a low share of pAkt- expressing cells and, vice versa, for 
CD45low - cells.  These results suggest the existence of different patient groups among MM patients, 
with predominantly activated either JAK/STAT3 or PI3K/Akt pathway. 
We proceeded to treat the patient-derived tumour cells with 17DMAG ex vivo. After 24h, 
the levels of caspase 3 were measured as an estimate of the drug -induced apoptosis. Notably, 
CD45high patient samples had a reduced number of pSTAT3+ cells and the elevated number of 
caspase 3+ cells upon the treatment with 17DMAG. Thus, we could confirm that the CD45high 
pSTAT3+ cells were more sensitive to the Hsp90 inhibitors than the CD45low - cells, which is in line 
with our observations of the cell lines. Besides, this experiment further confirmed our hypothesis 
that the cells with the activated JAK/STAT3 pathway (as measured by the presence of pSTAT3), 
are mostly responsible for the 17DMAG-induced apoptosis. 
To further prove that the activated JAK/STAT3 axis confers sensitivity to the Hsp90 
inhibition, we utilized a STAT3C-transfected subline of a MM cell line U266. When treated with 
17DMAG, the STAT3C - subline was more resistant to apoptosis than the mock-transfected subline. 
Thus, STAT3C protected myeloma cells from the apoptosis induced by the Hsp90 inhibitor.  
STAT3C is retained in the nucleus longer as compared to the endogenous STAT3.434 
Therefore, the STAT3C protective function  might be executed at the level of the target genes. 
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Indeed, 17DMAG inhibited the expression of a STAT3-regulated gene Mcl1 stronger in the mock-
transfected cells than in the STAT3C clone.435  This observation provides some additional evidence 
that Hsp90 inhibitor 17DMAG induces cell death by inhibiting the phosphorylation of STAT3. It 
reduces the transcription of an Mcl1 anti-apoptotic protein, which is particularly important for the 
survival of MM cells436,437. Also, the basal levels of another anti-apoptotic protein Bcl2 increased 
when STAT3C was overexpressed in the myeloma cells. Although not affected by the 17DMAG 
treatment, this protein can provide additional protection against apoptosis induction.438-440 
 
 
  
In conclusion, our findings demonstrate that MM cell lines as well as patient samples differ 
in the CD45 expression and the activity of the IL6/STAT3 pathway. The constitutively activated 
IL6/STAT3 pathway makes myeloma cells vulnerable to the treatment with the Hsp90 inhibitors 
through the downregulation of the STAT3 phosphorylation and the expression of its target genes. 
On the contrary, MM cells relying on the PI3K/Akt signalling pathway are much more resistant to 
the treatment with 17DMAG (Figure 4). Thus, our data may suggest that the predominant activation 
of the JAK/STAT3 signalling pathway can be used as a predictive biomarker for the treatment 
response of myeloma tumours with Hsp90 inhibitors.  
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3.4 PAPER IV 
‘Development and characterisation of novel inhibitors of STAT-mediated transcription’ 
3.4.1 Background and Rationale 
 
STAT3 is a transcription factor that acts as a convergence point downstream of cytokine 
and growth factor receptors as well as non-receptor tyrosine kinases. It is phosphorylated in the 
cytoplasm (e.g., by JAKs, SRC) and then transported to the nucleus where it binds to the gene 
promoters. Many of the STAT3 target genes are cell type and context specific. The general vector 
of STAT3-dependent transcription points towards oncogenesis by promoting cell survival, 
proliferation, inhibition of apoptosis, immune suppression, tumour-promoting inflammation and 
metastasising.335 Although a lot of studies proved that STAT3 inhibition leads to cancer cell 
death,441 only few inhibitors have reached clinical trials, and none has been approved for clinical 
use.  
One of the reasons for the difficulties in the development of STAT3 inhibitors is the 
structure of the STAT3 complex. The transcription factor lacks easy-targetable domains, such as 
ATP-binding pockets frequently exploited during cancer-related drug development. Also, the 
STAT3 dimer is formed by large interacting surfaces and a lot of energy is required to break them. 
In spite of these difficulties, attempts to inhibit STAT3 are not abandoned and we undertook our 
own campaign to identify and develop low molecular weight compounds that affect the 
transcriptional activity of STAT3.  
 
 
3.4.2 Main Findings 
 
To construct a screening system we decided to use a pair of sublines derived from the colon 
adenocarcinoma line DLD1: A4 (where STAT3 was homozygously deleted) and A4wt (A4 
reconstituted with the exogenously expressed wtSTAT3 at the levels similar to DLD1).442 The A4wt 
cell line was stably transfected with the promoter reporter construct made containing 4x SIE upfront 
of the luciferase gene with a relatively short half-life. The reporter is activated is response to the IL6 
stimulation and can be inhibited by a commercially available inhibitor of STAT3 STATTIC and a 
pan-JAK inhibitor Pyr6. To increase the specificity of our screening in favor of the inhibitors of the 
STAT3 transcriptional activity (thus excluding inhibition of the upstream kinases), we treated the 
cells with the library compounds 1h after the stimulation with IL6. Since IL6 induces STAT3 
phosphorylation and nuclear translocation within minutes,443 we reasoned that after 1h of 
stimulation the  JAK kinases would become inactivated by the phosphatases.  
After hit selection, we assessed the compounds for their chemical promiscuity and selected 
the compounds with a pharmacological potential. We carried out additional biological assays to 
filter out the compounds with a highly unspecific mechanism of action (e.g., the inducers of rapid 
cell death, general transcription inhibitors, compounds highly toxic for the non-transformed 
fibroblasts). Also, we utilized the screening system to determine the IC50 of the inhibitory activity of 
the compounds. Simultaneously, we used a STAT3-null subline A4 transfected with the same 
reporter and stimulated with IFNγ, to study whether the compounds had a differential effect on the 
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IFNγ-induced luciferase activity (Figure 5 illustrates the complexes formed in response to IL6 and 
IFN𝛾 stimulations). 
The compounds were docked against the SH2 domain of STAT3 to assess their potential to 
bind it. Although the SH2 domain is one of the most popular sites for STAT3 inhibitors binding, we 
did not restrict our selection to this particular site, as there are other loci described as crucial for the 
STAT3 transcriptional function. Therefore, based on the initial biological tests and also on the 
results of docking, we chose 4 compounds for further development and named them KI 1, KI 4, KI 
12 and KI 16. 
 
 
Next, the impact of the compounds on the viability of 4 cancer cell lines with or without 
constitutively activated STAT3 was assessed. The STAT3-dependent cell lines MDA-MB-468 and 
DU145 have documented autocrine production of cytokines and growth factors that leads to STAT3 
constitutive phosphorylation (such as IL6444,445 and EGFR446,447). These cell lines were more 
sensitive to our experimental compounds than the cells without the activated IL6/STAT3 pathway 
(MCF7 and PC3). Moreover, the sensitivity to the drugs was proportional to the basal levels of 
pTyrSTAT3 in whole cell lysates that gives an indication that the compounds induced the cell death 
through STAT3 inhibition. 
Since STAT3 oncogenic function is exerted to a large extent through its transcriptional 
activity, we further tested whether the compounds can inhibit the genes induced in our screening 
system (A4wt cells, treated with IL6).435 We chose a panel of 4 genes (MUC1, JUNB, BCL3, 
TRIM15) regulated by IL6 as determined by a microarray (J. Yang, unpublished). Cells were pre-
treated with the compounds and then treated with IL6.  We could see that the IL6-induced gene 
expression was abolished. These compounds affected the transcription of different genes with 
varying efficiency which can be explained not only by yet un-optimized chemical structures of the 
drugs, but also by a complex regulation of these genes promoters.  
A different gene set was used to assess the effect of the compounds on gene transcription in 
the STAT3-dependent cell lines MDA-MB-468 and DU145. When treated with the compounds for 
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4h, we observed the downregulation of BCL3, CCND1 and MUC1 genes, although with different 
efficiency. Since these cell lines express pSTAT3 constitutively, they might require longer 
treatment to achieve prominent downregulation of the genes.  
To further understand the mechanism of action of the compounds, we assessed how they 
affected the phosphorylated levels of STAT3 and its closely related protein STAT1. When using 
IL6 to induce the STAT3 phosphorylation on Tyr705, the compounds did not affect pSTAT3 (apart 
from the compound KI 16, which inhibited pTyr705STAT3 in a dose-dependent manner). When 
applied in the MDA-MB-468 and DU145 cell lines without external activation of STAT3, KI1 and 
KI16 demonstrated some activity against the phosphorylated STAT3. 
Taken together, we identified several compounds that inhibited STAT3 transcriptional 
activity. KI1 and KI4 resemble the structure of Erlotinib, whereas KI12 and KI16 are unique 
structures for STAT3 inhibitors. Consistently with its alignment with the SH2 domain of STAT3 
KI16 inhibited the IL6-induced phosphorylation of STAT3.  
 
3.5 GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
Targeted therapy was thought to revolutionize the treatment of cancer by selectively killing 
cancer cells and sparing normal cells. It would result in minimal side effects. The concept worked in 
experimental systems, but turned out  less efficient in patients.448 First, the blame was laid on the 
absence of the molecular diagnostic criteria that led to the overtreatment of a large group of patients 
when only a small fraction could benefit from a drug. This problem was addressed, and the patients 
receiving a drug were screened for a targeted mutation.449 However, it did not lead to the expected 
success.450 The same mutation in different cancer types may result in a differential response to the 
same therapy. Taken together, it points out that cancer is extremely intricate, and it is unlikely to be 
defeated with a single agent. The efficiency of the available therapeutics can be increased when a 
set of three biomarkers is used that assess the  prognosis of the intrinsic resistance, prediction the 
most efficient therapy and the evaluation of the clinical response.451  
Three papers of this thesis address the issue of biomarkers (papers I-III), while paper IV 
describes our attempt to hit cancer cells by knocking off one of the central nods in the signalling.  
Empirical evidence showed that IFNs have a potent biological activity. Therefore, they 
were used to treat cancer and infectious diseases in the absence of better alternatives. IFN use 
declined as more effective drugs were introduced, and now it is used in several specific types of 
cancer only. This can be partially explained by its limited efficiency as a single treatment agent, but 
also by some side effects of the IFN treatment tilting the balance of risk vs benefit against its use.  
It appears that although almost all cells are growth arrested upon treatment with IFN, the 
direct pro-apoptotic effect on tumour cells occurs in a limited number of cancers.452 In our study 
(paper I) we use two cell line models: the multiple myeloma cell line U266 and the human 
keratinocyte cell line Rhek-1, that both undergo apoptosis upon the treatment with IFN. What 
determines whether the cells (even of the same origin, e.g. multiple myeloma) will undergo 
apoptosis is not yet clear. Using pharmacological inhibitors of different pathways, we have 
demonstrated that phosphorylation of STAT1 is essential for the IFN-induced apoptosis. We have 
confirmed this observation by overexpressing the STAT1 dominant-negative mutants. Both 
chemical and genetic inhibition of the STAT1 phosphorylation caused a partial protection from the 
IFN-induced apoptosis. The complete protection was achieved when, at least, two signalling 
pathways were inhibited (e.g., the JAK/STAT1 and the PI3K/Akt pathways).  
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After the discovery of the JAK/STAT pathway as the main cascade propagating the IFN-
signal, it soon became obvious that IFN induced other pathways as well. Among them, for example, 
is a MAPK/p38 pathway that was shown to be essential in the IGSs transcription separately from 
the JAK/STAT pathway activity.453,454 The PI3K/Akt pathway has also been extensively studied in 
relation to the antiviral effects of IFNs through the transcriptional regulation of ISGs. Akt 
deficiency impaired the translation of ISGs, but not the transcription, showing that JAK/STAT-
induced transcription is an independent event.455 
In our study, we show that PI3K is important for the IFN-induced apoptosis and that its 
pharmacological inhibitors do not affect the JAK/STAT pathway activity. In a similar vein, 
previous reports demonstrate that PI3K pathway signals downstream of JAKs, but independently of 
the JAK/STAT arm. Deletions of Akt (either of one or both alleles) had a dose-dependent inhibitory 
effect on the translation of ISGs and an antiviral function of IFNs, but no effect on the 
phosphorylation, nuclear translocations, or activity of STATs.455  
Recent studies have shown that type I IFNs can induce autophagy in some cancer 
cells.456,457 IFNβ-triggered apoptosis was induced independently of the PI3K-regulated autophagy in 
a glioma model. In this case, autophagy induction was a pro-survival mechanism that counteracted 
the pro-apoptotic effect of IFNβ.458 Rapamycin, an mTOR inhibitor used in our study, is a known 
inducer of autophagy.459 Akt inhibitor X (also known as 10-NCP) has been found to induce 
autophagy in an Akt- and PI3K-independent manner.460 In other systems, Ly294002 (a PI3K 
inhibitor) was shown to block IFN-induced STAT1- and STAT2-dependent autophagy in a range of 
cell lines.456 At the same time, this compound induced autophagy and cell death in other cell lines 
independently of the IFN treatment.461 It is recognised now that autophagy in cancer cells can both 
protect from and induce cell death depending on the context, applied drug, the stage of tumour 
development, etc.462 Autophagy in MM may also play both protective and pro-apoptotic roles.463 
We have not addressed the autophagy regulation upon the IFN treatment in our system; it is likely, 
however, that autophagy might protect multiple myeloma cells from the IFN-induced cell death.  
Apelbaum et al. performed an siRNA screening upon treatment with type I interferon to 
determine which genes were important for the IFN-mediated cell death. They confirmed our 
observation that STAT1 (as well as JAKs, IFNARs, and IRFs) were of utmost importance, but, 
surprisingly, they did not find that RNAi-mediated inhibition of any of the PI3K downstream targets 
protected from the IFN-induced cell death.464 Tthe same group earlier reported the discovery of an 
IFN mutant with much higher affinity to IFNAR1 than the wild type and with 100-fold decreased 
EC50 for the induction of apoptosis.465 Antiviral properties of the mutant IFN were hardly affected, 
demonstrating again that the induction of apoptosis and of antiviral state are regulated separately 
from each other.  
The use of IFNs as anti-cancer drugs was based largely on empirical evidence. Our study 
exemplifies the importance of delineating the exact mechanisms of the anti-tumour activity of 
drugs, including IFN. On one hand, this might aid in understanding the mechanisms of resistance, 
and, on the other hand, will provide the basis for appropriate drug combinations in individualised 
anti-cancer therapy. Since a tumour is currently viewed as a heterogeneous organ, where the 
dominance of a particular clone is governed by intricate mechanisms, it is thought that a 
combination of traditional radio- and chemotherapy with targeted drugs (simultaneous or 
sequential) is the future of clinical oncology.466  
External immune system activation during immunotherapy either requires IFN for the 
immune cell activation ex vivo or the immune cells use IFN as an effector.  Therefore, the use of 
IFNs as part of complex immunotherapy is not improbable. Considering our findings that the PI3K 
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and mTOR inhibitors inhibit the IFN-induced cell death, one should be careful when designing the 
combinations of targeted therapies with IFNs or with immunotherapy.467,468 
From a wide perspective of tumour biology and treatment sensitivity, this study leads to two 
general conclusions. Firstly, a signal (such as IFN) generates a massive response in a cell, and 
cooperation between seemingly separate pathways determines the nature of the response. Secondly, 
a canonical pro-tumourigenic pathway can participate in orchestrating the pro-apoptotic effect when 
interacting with other signalling pathways. These findings are important for the rational use of IFN. 
 
In the study described in Paper II we investigated the mechanisms of intrinsic drug 
resistance of the cells and demonstrated that it correlated with the expression of a set of interferon-
stimulated genes. Several groups came across a similar observation using tumour samples of 
different origin (see section ‘IRDS in cancer’). The analysis of the available expression data 
demonstrates that ≈30-40% of breast, head and neck, ovarian carcinomas, as well as a fraction of 
glioblastomas and hematological tumours express IRDS, a set of genes initially described by 
Khodarev et al., and considered to be a marker of drug resistance. About 50% of tumours bearing 
IRDS are more aggressive and have worse prognoses than tumours without IRDS (Khodarev et al., 
unpublished).  
Several studies conclude that STAT1 is the main inducer of the IRDS.469 Although also 
induced in our system (both in MCS and in crowded monolayers), we found that STAT1 is 
disposable for the expression of ISGs, at least in the HCT116 cell line. In the other system (U3A-
2fTGH pair), STAT1 expression contributed to the induction of ISGs, but was not necessary for it, 
since a STAT1-null subline U3A still showed upregulation of the genes and protein levels of 
STAT2 and IRF9. According to our data, IRF9 upregulation is sufficient for both ISGs induction 
and for driving drug resistance. Since knockdown of IRF9 and STAT2, but not STAT1, led to the 
reduced expression of ISGs, we hypothesise that the IRF9/STAT2 complex is a transcriptional 
regulator of ISGs. Notably, we were not able to detect the phosphorylated forms of STAT proteins 
when cultured over time, suggesting that unphosphorylated ISGF3 (U-ISGF3) or U-STAT2/IRF9 
drive the ISGs in this system.151  
There is a view that tumours and cell cultures secrete low levels of IFNs in response to the 
exposure to DNA of neighbouring cells that undergo necrosis or in response to the DNA of 
oncogenic viruses.470 In our system, though, no traces of IFNs were detected, neither on the mRNA 
level nor in the secreted form. As additional evidence, we demonstrate that cells without STAT1 are 
not able to adequately react to IFNs by inducing IRF9 levels, once again demonstrating that ISGs in 
our system are unlikely to be driven by IFN. 
The question remains as to why the role of IRF9 is undermined in the analysis of the 
publicly available expression data.470 The reason for this might be that IRF9 does not have a 
transactivation domain and, therefore, cannot solely drive the transcription of ISGF3-regulated 
genes while STAT1 homodimers are strong transcriptional enhancers. As shown in paper II, 
overexpression of IRF9 about two- or three-fold led to the induction of ISGs and drug resistance. 
This might indicate that moderately increased IRF9 levels stimulate complex formation with 
STAT1/STAT2 or solely with STAT2 to drive gene transcription.143,144 As reported by Luker et al., 
overexpression of IRF9, but not STAT1 and STAT2, confers drug resistance. The same group also 
reported that IRF9 was overexpressed in 50% of breast carcinomas resistant to antimicrotubule 
agents.471 This result is consistent with our own data, where siRNA-mediated downregulation of 
IRF9 had a more pronounced effect on the transcription of ISGs than the downregulation of STAT2. 
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Taken together, the role of IRF9 in mediating drug resistance might still be underestimated. 
Unveiling the mechanism of IRF9 induction and ISG-induced cell death will allow evaluating the 
potential of IRF9 as a resistance biomarker. Additional experimental and epidemiological studies 
are needed to reveal whether IRF9 promotes any other phenotype than treatment resistance.  
 
 In paper III, we show that a typical pro-oncogenic pathway predisposes to the drug 
sensitivity. Hsp90 inhibitors were developed as anti-cancer drugs based on the assumption that 
cancer cells require high chaperoning activity. Multiple proteins involved in oncogenesis have been 
shown to be clients of the Hsp90 complex, thus potentially rendering cancer cells vulnerable to the 
Hsp90 inhibition while sparing normal cells. In our study, we observed that MM cells have 
predominantly activated either the IL6/JAK1/STAT3 or the PI3K/Akt pathways, probably due to 
IL6-regulated expression of CD45 which shuts down the PI3K/Akt signalling. Both pathways being 
oncogenic, it appears that the IL6/STAT3 pathway is particularly dependent on the Hsp90 activity, 
whereas the PI3K/Akt pathway is less dependent. This finding was also applicable to primary cells 
where we could identify a subgroup with high CD45 and pSTAT3 expression and with low CD45 
and high pAkt expression. The CD45high population was sensitive to the Hsp90 inhibition, showing 
signs of apoptosis and decreased pSTAT3 levels upon the treatment with 17DMAG. Moreover, the 
external induction of the JAK/pSTAT3 pathway was sufficient to sensitise the cells to the Hsp90 
inhibitors, as was demonstrated by prolonged treatment of a resistant CD45- cell line LP1 with IL6. 
Taken together, we observed that an active IL6/STAT3 pathway might serve as a predictive factor 
for the sensitivity to Hsp90 inhibitors.  
When the primary chemotherapy or even targeted therapy is applied, it is common that cells 
develop resistance through the induction of STAT3.222,223,472-474 In this case, it might be reasonable 
to apply the inhibitors of STAT3 or Hsp90 inhibitors to reach further tumour regression. The use of 
Hsp90 inhibitors for the co-treatment with other conventional drugs has already been found 
beneficial.475,476 Surely, the dependence of pSTAT3 signalling pathway on Hsp90 should be further 
investigated to understand whether this phenomenon applies to other cancer types. Although 
STAT3 was described as a client of Hsp90,477,478 inhibition of STAT3 phosphorylation by Hsp90 
inhibitors occurs most probably due to degradation of JAK1 and JAK2; therefore, the mode of 
activation of STAT3 in a particular cancer type should be taken into consideration.479,480 
Importantly, the redundancy in the chaperoning pathway should be considered when inhibiting 
Hsp90.481,482 
 
In Paper IV we describe the identification and initial preclinical characterisation of novel 
inhibitors targeting STAT3 signalling in cancer. We identified the inhibitors by screening a 
compound library in a cellular system designed to monitor STAT3 transcriptional activity. Using 
this system allowed us to account for the drug penetration and solubility issues, but we had to 
address the issue of the primary drug target later. Therefore, we applied very stringent criteria to the 
lead selection from the primary and secondary screenings and the counter-screens, and also 
performed the compound structure analysis to identify the most promising and structurally novel 
compounds.  
By assessing the expression of STAT3-target genes, we could see that all selected 
compounds inhibited the IL6-induced expression of MUC1, BCL3, TRIM15, and JUNB genes. Also, 
the compounds inhibited the transcription of the IFNγ-induced genes, which indicates that the 
compounds are likely to be more specific to STATs than to the upstream kinases.  
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When we performed the docking of the studied compounds to the SH2-domain of STAT3, 
we did not detect high glide scores for the compounds KI 1, KI 4, and KI 12. It is consistent with a 
Western blotting analysis that showed that these compounds (KI 1, KI 4, and KI 12) did not 
influence the IL6-induced phosphorylation of STAT3. On the other hand, KI 16, which had the 
highest glide score of the four compounds, reduced the levels of pSTAT3. Interestingly, none of the 
compounds (including KI 16) had high gliding scores when docked against the SH2 domain of 
STAT1 or against JAK1. 
It should also be noted that the compounds tested in the biological assays were identical to 
the ones in the library and have not been subjected to any chemical modification yet. The average 
molecular weight of these compounds is ≈300 (for comparison, Gleevec is 493.6). Thus, there 
remains the opportunity for structure-activity relationship development in the functional group. 
Our findings indicate that it is likely that the compounds we selected act through different 
mechanisms, which remains to be studied. Using the docking, we can assess the potential of the 
compounds to bind only to specific domains with available crystal structures (for example, the SH2-
domains for STAT3 and STAT1), but not to the protein as a whole. A common method to verify the 
drug binding to its target is the assessment of protein stability upon subjecting it to increasing 
temperatures (thermal shift assay and CETSA).483-485 On the other hand, to get a more 
comprehensive idea of the drug effect on the cells, a gene expression-based approach is widely 
utilised. After generating a drug-specific gene signature in a cell line(s) of interest, it is queried 
against disease-specific and drug-specific expression data in the Connectivity Map Project, allowing 
for all-embracing analysis of the compound effects.486 Both physical binding of the candidate 
compounds to STAT3 protein and the functional analyses should be performed to elucidate the 
mechanism of action and to predict side effects of the compounds under study. 
Finally, another question which often arises in conjunction with the development of STAT3 
inhibitors is the feasibility, novelty, and the potential of the attempts. Considering the abundance of 
the published compounds claimed to inhibit STAT3 while none has been approved as a drug, it is 
reasonable to admit that STAT3targeting is a difficult task. On the other hand, STAT3 is way too 
attractive a target to be abandoned, and, regardless of how much effort it takes, there will always be 
dreamers who will keep trying. After all, everything is impossible until someone has done it, and I 
strongly believe that any big discovery is based on multiple small discoveries. Therefore, with every 
developed compound we learn a bit more about STAT3 and come a bit closer to the development of 
a drug. 
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4 CONCLUSIONS 
 
1) IFN induces several signalling pathways in the cells, and a cooperation of at least two 
pathways (the JAK/STAT1 and the PI3K/Akt) is necessary to trigger apoptosis in a 
multiple myeloma cell line. Phosphorylation of STAT1 is required for the pro-
apoptotic effect of IFN (Paper I). 
 
2) Multicellular spheroids express a set of genes that belong to the signature previously 
associated with therapy resistance. Crowding of cells of different origin also results in 
the upregulation of the IFN-stimulated genes without the production of IFN. The 
genes are regulated by IRF9 and STAT2 while STAT1 is dispensable. 
Overexpression of IRF9 alone leads to multidrug resistance in a colon carcinoma 
model (Paper II). 
 
3) The IL6/STAT3/CD45 and the PI3K/Akt pathways are mutually exclusive in 
multiple myeloma cell lines. Hsp90 inhibitors induce apoptosis in multiple myeloma 
cells through downregulation of STAT3 phosphorylation and and the expression of 
its target genes. The IL6/STAT3 pathway activity and the expression of CD45 
phosphatase predict the sensitivity of multiple myeloma cell lines and ex vivo treated 
primary myeloma cells to Hsp90 inhibitors (Paper III). 
 
4) We report the development of novel inhibitors of STAT transcriptional activity in 
cancer cells. Four investigated compounds differently affect phosphorylation of 
STAT3 and are likely to have different mechanisms of action. Regardless of their 
effect on pSTAT3, the compounds inhibit the expression of STAT-regulated genes 
(Paper IV). 
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